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Abstract 
This Thesis entitled ‘The synthesis and study of novel fluorescence probes for 
NTR’ is divided in 7 chapters. Chapter 1, provides an introduction to cancer, 
reductive stress and some techniques to detect the tumour cells. A range of relevant 
examples of fluorescence sensors for NTR are also given. This Chapter also 
includes the objectives for the research conducted in Chapters 2, 3 and 4. 
Chapter 2 describes the synthesis of a set of novel fluorescence sensors where 
variation of naphthalimide substituents is described. The synthesis of each 
compound is discussed, followed by an evaluation of their photophysical 
characteristics and response to nitroreductase (NTR) in a biological setting. 
Chapter 3 explores synthetic modifications to the compounds described in Chapter 
2 in order to increase NTR sensitivity. A set of novel fluorescence sensors are 
described where the sensitivity is modulated using a range of reducible 
nitroaromatic moieties. The synthesis of each compound is also discussed, in 
addition to the preliminary test for NTR. 
Chapter 4 discusses a novel family of NTR sensors amenable to bioconjugation 
through various biocompatible linkages. Structural modification of compounds 
described in Chapter 2 provides access for conjugation to peptides, sugars, 
oligonucleotides and various other important biomolecules. The synthesis of each 
compound is discussed. 
Chapter 5 outlines the overall conclusion of the work carried out during this 
research. 
Chapter 6 describes general experimental procedures and the characterisation of 
each compound discussed throughout the thesis.  
Finally, in Chapter 7, the Appendix shows all supporting information. 
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Chapter 1 Introduction 
1.1 Cancer 
 
1.1.1 What is cancer 
 
Cancer is a disease of human cells. Our body is made up of countless cells. The 
body will automatically reproduce new cells, so that we can grow, replace old cells, 
or repair damaged cells due to injury. This mechanism is controlled by genes. But 
if the control mechanism of those genes are damaged, cancer will appear. Cancer 
can appear anywhere in human bodies. This damage have the opportunity to occur 
in our lifetime, and a small number of people are inherited from their parents to 
the damaged genes [1]. Normally, the cells will split and multiply in a very orderly 
manner. These cells can grow and divide to form new cells or tissues when our 
bodies need them. When cells get older or become damaged, they will die and new 
cells take their place. But once the cells loss of control, it will continue to 
reproduce, accumulate in the body into a tumor. When tumors develop, cells 
become more and more abnormal, and the fresh cells form when there is no space 
for them. These extra cells can divide and grow themselves without stopping and 
may form growths. Tumors can be divided into benign and malignant, malignant 
tumors commonly known as cancer [2]. Benign tumor cells will stay at their 
position and will not spread to other parts of the body. Malignant tumors contain 
cancer cells. When it is initially formed, it will keep in the original position, which 
is called in situ cancer. But if the cancer cells are not treated well, it will destroy 
the surrounding tissue and spread to other organs to become invasive cancer 
(Figure 1-1). 
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Figure 1-1: The growth of cancer cells affects the surrounding tissue 
 
1.1.2 The characteristics of cancer 
 
In 2000, Douglas Hanahan and Robert A. Weinberg published an article in Cell: 
The Hallmarks of Cancer [3], a review of the six basic characteristics of tumor 
cells: self-sufficient growth signal; anti-growth signal is not sensitive; resistance 
to cells death; unlimited ability to replicate; persistent angiogenesis; tissue 
infiltration and metastasis. In March 2011 issue of Cell magazine, this two 
professors had published an updated version of the overview: Hallmarks of Cancer: 
The Next Generation [4], which outlined the hot spots in oncology and progress of 
last 10 years, based on the original six characteristics, they added four 
characteristics, including to avoid immune destruction, promote tumor 
inflammation, cell energy abnormalities and genomic instability and mutation. 
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Figure 1-2: The characteristics of cancer and its targeted therapy 
These ten characteristics which distinct tumor cells from normal cells were the 
target of treatment of cancer, and were the basis of biological targeted therapy 
(Figure 1-2). It is well known that cancer cells are almost rampant in every part of 
the body, from the brain to the various organs, from the epidermis to the bones. 
Cancer cells are not invaded from the outside, they are the same as the normal cells 
that make up the organs of the human body, but the difference is that the changes 
in the structure and function of the cancer cells make them aggressive and 
destructive. 
 
Self-sufficient growth signal 
If a cell wants to change its current state, it must receive a series of related 
instructions, then the process can be carried out. This instructions are called signal 
molecules. Signal molecules are carried out by binding to the receptors on the 
target cells and changing the state of the cells. 
In this respect, cancer cells are distinctly different. Cancer cells have the ability to 
make their own orders, that is to say, they can be their own synthetic growth and 
differentiation of the growth signal required, without relying on exogenous signals. 
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Scientists have found that the ability to synthesize PDGF (platelet-derived growth 
factor) and TGFα (tumor growth factor alpha) is found in cancer cells in 
Neuroblastoma and Malignant Sarcoma, respectively [5]. 
 
Anti-growth signal is not sensitive 
In addition to the growth of the human body signal, there is still a growth inhibition 
signal. At different stages of cell division, some molecules detect the status of these 
cells, depending on the circumstances to determine the development of cells: 
continuing to grow differentiation, or still at rest, or loss the ability of growth and 
differentiation into the late mitosis. So that the normal cells maintain a dynamic 
balance of the state, the orderly growth and differentiation. For cancer cells, if they 
want to continue to grow and divide, they must escape the monitoring of these 
molecules. Their primary strategy is to mutate these molecules through gene 
mutations to achieve the purpose of suppressing anti-growth signals [6]. 
 
Resistance to cells Death 
Escape apoptosis is the ability almost all types of cancer cells have. Signal 
molecules responsible for apoptosis can be broadly divided into two categories: a 
class of monitoring molecules as described above, such as a protein called p53 
which is one of the most important members [7]; the other is responsible for the 
implementation of cell apoptosis death. The former monitor the cells inside and 
outside the environment, once they found abnormal cells, the latter command. 
Apoptosis is the main barrier for people against cancer. Cancer cells are state of 
abnormal cells to monitoring molecules, and the main method for cancer cells to 
escape apoptosis is to mutate the p53 protein and make it inactive. 
 
Unlimited ability to replicate 
In cell culture experiments, it was observed that most normal cells can only divide 
around 60 times. Scientists have confirmed that cell division is related to the 
sequence of thousands of bases at the end of chromosome [8]. This sequence 
becomes telomeres, and the sequence will decrease by 50 to 100 bases every time 
a fraction is divided. As the number of fractions increases, telomeres become 
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shorter and shorter, and the result is that it can no longer protect the chromosome 
Of the end, the chromosome cannot be successfully copied, leading to cell aging. 
The results show that all types of cancer cells (Figure 1-3) have the ability to 
maintain telomeres [9]. This ability is mainly achieved by overexpression of 
telomerase. The primary function of telomerase is to add the desired base to the 
end of telomeres to ensure that telomeres are not reduced by replication. 
 
Figure 1-3: Breast cancer cells are splitting 
 
Persistent angiogenesis 
Blood vessels is very important to cells. In general, angiogenesis is finely regulated 
during tissue formation and organogenesis, and angiogenesis is temporary in this 
case, and angiogenesis is stopped when the physiological process is complete. The 
signal molecules that promote and inhibit angiogenesis are usually in a balanced 
state. 
Cancer cells to achieve the ability of sustained neovascularization is to break 
through this balance. Scientists have found in many types of tumors that some of 
the signal molecules that promote angiogenesis, such as VEGF (vascular 
endothelial growth factor) and FGF (fibroblast growth factor), are much higher 
than the corresponding normal tissue controls. The expression of signal molecules 
such as thrombospondin-1 or beta-interferon decreases [10]. 
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Tissue infiltration and metastasis 
Most of the cells in the human body need to adhere to a specific extracellular 
matrix to survive and function properly, such as epithelial cells and endothelial 
cells. Once out of the cell extracellular matrix it will occur apoptosis. The molecule 
that adhere these cells to the extracellular matrix or molecules is called cell 
adhesion molecules, which act as anchors in the port. 
E-cadherin is one of the most deeply studied cell adhesion molecules [11]. It is 
widely expressed in epithelial cells, and found in the loss of activity in most 
epithelial cell carcinoma. Scientists believe that E-cadherin plays an important role 
in inhibiting the invasion and metastasis of cancer cells in epithelial cell carcinoma. 
The loss of activity indicates that cancer can develop to other places. 
 
Figure 1-4: How tumor cells are transferred to other tissues (from the Art of 
MBoC3 1995 Garland Publishing, Inc) 
 
Avoid immune destruction 
Both the innate immune and the adaptive immune system play an important role 
in tumor clearance. While solid tumors have different functions to escape the 
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immune system of the human body, ensuring that they are not killed and cleared 
by immune cells such as T cells, B cells, macrophages and natural killer cells. 
 
Promote tumor inflammation 
Over the past several decades, a number of studies have confirmed the relationship 
between the inflammatory response and the pathogenesis of cancer: the 
inflammatory response can provide various biological activating molecules for the 
tumor microenvironment, including, for example, growth factors which can 
maintain the proliferation signal of cancer cells , Survival factors which inhibit cell 
death, angiogenic factors and extracellular matrix modulating enzymes which may 
favor vascular growth, cancer cell infiltration and metastasis, and other induction 
signals which may activate other characteristics of EMT and cancer cells. 
 
Genomic instability and mutation 
The complex process of tumors can be rooted in the continuous mutation of cancer 
cell genes. When a large number of gene mutations happen to induce 
tumorigenesis, cancer cells often increase their susceptibility to inducible gene 
mutations, thereby speeding up their gene mutation [12]. Although the types of 
gene mutations in different types of tumors are different, they can be found to be 
stable and to repair functional deficiencies in genomic DNA. Suggesting that a 
major feature of tumor cells is the inherent genomic instability. 
 
Cell energy abnormalities 
Even in the presence of oxygen, cancer cells produce energy mainly from 
anaerobic glycolysis.  
Through the above, we know that one of the characteristics of cancer cells is 
uncontrolled reproduction. In the process of cell proliferation, the tumor cells will 
absorb nutrients and oxygen to suit their own growth. Since the body's blood 
oxygen content is fixed, when the tumor cells are infinitely replicated, it is bound 
to absorb a lot of oxygen and thus cause oxygen concentration around tumor cells 
gradually decreased, which formed a tumor hypoxia. In fact, tumor hypoxia occurs 
 8 
 
in the vast majority of tumor cells, and is another major feature of the tumor 
microenvironment. 
 
1.2 Tumor hypoxia 
 
Tumor hypoxia is the situation which tumor cells have used all of the oxygen. As 
the tumor grows, it rapidly consuming the blood supply, and leave oxygen 
concentration of some parts of the tumor much lower than in healthy tissues. Just 
like the Figure 1-5, the oxygen concentration of hypoxic area is much lower than 
it in normal cells. The hypoxic microvascular disease in solid tumors is due to the 
rapid proliferation of tumor cells has consumed the available oxygen in tumor 
vasculature [13]. This causes solid tumors that have reduced oxygen availability 
to proliferate uncontrollably and show unusual structural and functional behaviour. 
The longer distance from the nearest blood vessels, the less chance to get the 
available oxygen (Figure 1-5). The distance between tumor hypoxic area and 
disorganized vascular is longer than the distance of diffusion oxygen (which is 
around 100 to 200 μm, depending on the oxygen concentration in the local tissue) 
[14]. 
When the partial pressure of oxygen (PO2) is lower than the normal physiological 
level, the tumor microenvironment will show hypoxia. Studies have shown that 
most of the tumor cells around the oxygen partial pressure of 7.5 mm Hg [15], 
while the PO2 value of normal tissue is more than 40 mm Hg, so hypoxia is a 
common phenomenon in the tumor microenvironment. There are many reasons for 
hypoxia in microenvironment, mainly in the following cases: (1) because most 
tumor cells are in high metabolic and rapid proliferative state, oxygen consumption 
is much larger than supply, resulting in a decrease in oxygen content in 
microenvironment, and ultimately the formation of hypoxia microenvironment. (2) 
hypoxia of tumor cells will cause secretion of vascular endothelial growth factor 
(vascular endothelial growth factor, VEGF) and other vascular factors, which can 
speed up tumor angiogenesis and increase the density of tumor microvessels that 
cannot regulate the blood flow, resulting in excessive perfusion hypoxia; in 
addition, microvessels within the tumor are not evenly distributed, the distance 
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between microvascular tend to exceed the oxygen diffusion distance, resulting in 
oxygen cannot be effectively transported to the hypoxic site [16]. (3) Some of the 
tumor itself and radiation therapy can lead to anemia in the body, haemoglobin 
reduction is a common phenomenon for cancer patients. One study found that 
when the haem is less than 10 ~ 12 g / d, the tumor supply of oxygen will be 
significantly declined and cause hypoxia [17]. 
It has been found that hypoxic tumor cells have a blocking effect on chemotherapy 
and radiation treatment and presents a huge challenge to cancer therapy for the 
following reasons: (1) since hypoxic tumor cells are very far away from blood 
vessels that anticancer drugs cannot reach to these areas; (2) the hypoxic tumor 
cells which can survive in hypoxic environment can show much more tolerance to 
hypoxia and might upgrade or renew to more malignant tumor cells; (3) when a 
treatment kills oxygenated cells, it will allow hypoxic cells to be reoxygenated and 
start to grow, which make a very important contribution to the growth of tumor 
cells [18]. 
On the other hand, hypoxic environments also help us identify and distinguish the 
tumor cells. Therefore, estimating the tumor hypoxia degree is one of the most 
important ways to predict therapy efficacies [19]. 
 
Figure 1-5: Oxygen concentration in hypoxic cells and normal cells 
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The formation of hypoxia in the tumor leads to a reduction of oxygen in the tumor. 
In this case, the nicotinamide adenine dinucleotide (NAD) in the molecule is 
converted into its reduced form (NADH) due to insufficient oxygen concentration, 
which leads to a new situation, reductive stress. 
 
1.3 Reductive stress 
 
Nicotinamide adenine dinucleotide (NAD) is a widespread biological redox 
cofactor in cells. The oxidized form of NAD carries a positive charge and is written 
as NAD+ while the reduced form is NADH (Figure 1-6). Reductive stress is 
induced by conditions which promote the formation of excessive intracellular 
NADH. 
In aerobic cells the decomposition of fuel molecules is associated with the 
reduction of NAD+ to NADH (Figure 1-6). Because during the transition which the 
oxygen growth was limited, an increased level of NADH builds up, and it is less 
efficient to oxidize NAD+ again because of reduced aerobic respiration. 
 
 
Figure 1-6: Transfer from NAD+ to NADH 
 
Therefore, reductive stress is related to respiratory inhibition and also it is related 
to the situation of cells become more reduced than the condition of normal cells.  
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Through the study of the reductive stress in the tumors, we found that it is 
particularly present in the case of tumor hypoxia, so it is very meaningful to use 
the appropriate methods to detect tumor hypoxia. The next section will be the 
discussion of the approaches for tumor hypoxia detection. 
 
1.4 Approaches for detection 
 
In 1955, Thomlinson and Gray found that there are hypoxic cells in malignant 
tumors; and in 1979, Brown and other scientists confirmed that the tumor hypoxia 
is divided into acute hypoxia and chronic hypoxia. This two different types can 
lead to different hypoxia related responses within the tumor, which can have an 
obvious and fast effect on tumor development and response to treatment [20]. 
Tumor hypoxia is divided into two parts, chronic hypoxia and acute hypoxia. 
Chronic hypoxia is when the tumor cells is too far away from the blood vessel 
under hypoxia situation because it is out of the distance of effective dispersion. On 
the other hand, acute hypoxia is because by tumor vascular network structure and 
function or intravascular blood reduced by or blocked. In addition, this status is 
caused by effective oxygen supply leads to functional oxygen deficiency and 
chronic hypoxia. The hypoxia caused by short-term blood flow interruption is 
known as acute hypoxia [21]. After many years of research, there is evidence to 
show that the presence of tumor hypoxic cells not only enhances the resistance of 
tumor to radiotherapy and chemotherapy but also makes the tumor more 
aggressive. Although people tried different methods to prevent tumor hypoxia, the 
clinical results are in need of further development. In recent years, many new 
methods have been developed to detect hypoxia, such as tumor vascular analysis, 
tumor metabolic degree determination, tumor cell DNA damage, hypoxic stress 
proteins analysis, radiotherapy assessment, radioactivity/ fluorescence staining 
labeling method, determination of oxygen pressure within tumors etc. Among 
these, three methods that are widely used today are: 1. Oxygen electrode direct 
measure; 2. Histomorphometric analysis; 3. Tumor markers [22]. 
 
Oxygen electrode 
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The oxygen electrode is one of the most widely used methods to detect hypoxia. 
This is the only method that directly determines tumor hypoxia, which reflects the 
oxygen concentration in tumor microenvironment. Now it is considered the gold 
standard to determine tumor hypoxia. At present, there are many clinical reports 
showing that oxygen electrode measurement is reliable, and the test result matches 
the tumor treatment effect. However, there are still many limitations: 1. Multi-
channel determination is necessary due to the tumor oxygen distribution of 
significant heterogeneity. 2. It is unable to distinguish between the tumorous and 
necrotic tissue within the hypoxic environment. 3. It will increase the rate of tumor 
transfer because the test requires insertion into the tumor microenvironment. 
This technology is measured by putting the cathode probe into the tumor, and 
measuring the oxygen partial pressure in a region of the tumor by detecting the 
current generated during the ionization of oxygen. Through the computer real time 
monitoring, it can be measured every 10 seconds.  
 
Histomorphometric analysis 
Histomorphometric analysis is the first method used in clinical practice. As the 
oxygen content of the tumor mainly depended on the blood supply of the tumor, 
so the hypoxia condition of the tumor is estimated indirectly by analysing the 
tumor tissue capillary space, vascular density, tumor necrosis and the closest 
distance between surrounding normal tissue blood vessels and tumor. It is 
relatively reliable to use this method to detect tumor hypoxia [23]. 
However, using this method to detect tumor hypoxia also has some disadvantages: 
1. it requires large tumor tissue blocks for analysis so will cause great pain for 
patients and increase the chance of cancer cell metastasis. 2. The main drawback 
is that the measurement was indirectly to tumor oxygenation and it cannot reflect 
the oxygen content of the tumor duo to the stopped flow or because of the oxygen-
depleted hemoglobin. [24] 
 
 
Tumor markers 
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Tumor markers are when cancer cells are in the process of occurrence, 
proliferation, differentiation, metastasis, necrosis and disintegration, it releases 
some substances due to the abnormal transcription, expression or secretion, the 
human body will also react abnormal to tumor growth and release some 
physiological substances such as proteins, peptides, hormones, enzymes, 
polyamines, oncogene products, viral antigens, etc., their presence or quantitative 
changes can prompt the nature of the tumors. Tumor markers can be used to 
identify cancer types, determine cancer staging, predict cancer growth rate, drug 
response selection, observation of treatment and prognosis etc. 
The ideal tumor markers must have the following characteristics: 1. High 
specificity, for tumor and non-tumor, it can identify accurately of up to 100%. 2. 
High sensitivity, it can be found in the very early stage of tumor. 3. The 
concentration of tumor marker in the body fluid is closely related to tumor size 
and clinical stage, and can be judged according to the prognosis. 4. Half-life is 
short, according to its level of monitoring, it can reflect the effect of treatment and 
whether the tumor recurrence or metastasis. 5. Easy to detect. 
Some common tumor markers are classified as:  
1. Embryonic antigen such as Carcinoma embryonic antigen, CEA for lung cancer 
detection [25]. The level of serum CEA in patients with lung cancer was 
significantly higher than that in normal control group and benign lung disease 
group, the positive rate of adenocarcinoma was more than 70% [26].  
2. Protein markers such as inhibitor of apoptosis proteins, IAP. Surviving is one 
of the most important member in IAP family, and it plays a significant role in the 
development of tumor. Surviving protein is almost expressed in all malignancies, 
whereas it doesn’t expressed in adult terminal differentiation tissues. Scientists 
Yagihashi et. using indirect ELISA to test the Surviving autoantibodies in 31 cases 
of NSCLC patients, and the positive rate was 58.1% [27].  
3. Carbohydrate markers. The glycosylation process in tumor cell was mutated, 
resulting in the change of glycoprotein of cell membrane or the change of the 
glycosyl sequence of glycolipid, and formatting a specific antigen which is 
different from normal antigen.  
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4. Enzyme markers. When the tumor occurs, the activity of the enzyme often 
changes greatly because: 1. The tumor cells or tissue itself will induce other cells 
produce abnormal content of the enzyme. 2. Tumor cell metabolism is very strong 
and increases cell permeability, making the enzyme of the tumor cells get into the 
blood. 3. The tumor makes some organs dysfunction, resulting in enzyme 
inactivation and excretion obstacles. Take Neuron-specific enolase, NSE as an 
example, NSE is an acidic protease that exists only in neurons and neuroendocrine 
cells. SCLC is a neuroendocrine-derived tumor, so NSE is one of the most valuable 
serum tumor markers of SCLC, the sensitivity is up to 40% to 70%, the specificity 
is up 65% to 80% [28].  
5. Hypoxia markers. Reductase overexpression is an important feature of tumor 
hypoxic cells, including nitroreductase, quinone reductase, azo reductase and so 
on. Reductive dependent hypoxia markers are mainly reduced by the fact that the 
probe is reduced by the reductase in the hypoxic region and the fluorescence 
changes. The hypoxia-sensitive groups used to reduce the dependent oxygen-
deficient probes mainly include nitro, quinone and azo. The principle is that with 
the great ability of reduction of tumor cells, when the electron affinity of nitro 
functional group such as nitroimidazole or quinone and azo active diffusion 
through the cell membrane, the functional groups were reduced under the 
reductase in cell, the reduced product is irreversibly bound to the macromolecular 
substance and remains in the tissue.  
Take nitroimidazole as an example (Figure 1-7), in the case of hypoxia area, the 
nitro group was reacted under the reaction of xanthine oxidase to form free anion, 
and then reduced by the nitroreductase into amino group, and bind with the 
biomolecule in the body to finally stay in the cell. While in the case of normal 
oxygen concentration, free anions will be oxidized into nitro group and excreted 
out of the body, resulting in the molecules unchanged. In this thesis, we are more 
focus on using Nitro reductase to detect tumor hypoxia. 
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Figure 1-7: Reaction of nitroimidazole under hypoxia 
 
In this thesis, we had introduced the classification of the methods for detecting 
hypoxia in the tumor, each method has its advantages and disadvantages, among 
them, hypoxia markers took a very important position in tumor hypoxia detection. 
Next we discussed some of the hypoxia markers that have been successfully 
developed. 
 
1.5 Hypoxia markers and fluorescence detection 
 
In 1976, Varghese et al. found that 2-nitroimidazoles are able to react with 
intracellular nucleophilic compounds to form novel molecules in hypoxia area as 
shown in Figure 1-7 [29]. The principle of nitroimidazole can act as a hypoxia 
activated prodrugs is that an enzymatic bioreduction resulting in the delivery of an 
electron to nitro group to activate it to a nitro radical. In normal conditions, the 
nitro group is back oxidized by oxygen in aerobic area which is changed to a 
superoxide anion and then transformed to hydrogen peroxide by superoxide 
dismutase (SOD) [30]. On the other hand, the pressures of oxygen can fall to below 
2.5 mmHg in hypoxia area [31], which inhibit the back oxidation and promote the 
further reduction of nitro radical to nitroso and finally amine derivatives. This 
reduction of the amine derivative can be used as a perfect substrates for covalent 
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attachment to intracellular nucleophilic compounds and remain in hypoxic cells 
compare to normoxic cells. 
In organisms, there are many reductase enzymes relating to the bioreduction of 2-
nitroimidazoles, which include one electron reductases such as NADPH-
cytochrome P450 reductase, cytochrome b5 reductase, xanthine oxidase and 
NADPH-nitroreductase, and two-electron reductases such as DT-diaphorase [32]. 
Instead of 2-nitroimidazole, there are still many functional groups that can be 
reduced by the various reductases such as 4-nitrobenzenes, nitrofuran, 
nitrothiofuran, azo linkages, quinones and 4-nitroimidazole. In fact, so many 
substrates and enzymes provide a variety of opinions for testing, we can not only 
synthesis the hypoxia targeting agents but also find out a way to selectively target 
tissues in which the aforementioned enzymes is located. 
With further research, we notice that the bio reduction method is always amenable 
to fluorescence detection. Fluorescence signals are widely used as an analytical 
tool for monitoring many biological processes in vitro and in vivo [33] [34], The 
biologically active probes provided herein utilize various functions such as 
nitroaromatic compounds, azo bonds, quinolones and N-oxides and it will be more 
focused on the detection of nitroaromatic compounds for hypoxia. 
The principle of the reaction of aromatic nitro compounds is the reduction of a 
nitroaromatic moiety present in the compound of a fluorophore. The electron of 
the nitro group is easy to be reduced by nitroreductase (NTR) enzymes [35]. This 
nitroreductase can be divided into two parts. First is oxygen insensitive 
nitroreductase, which means it can reduce nitro functional group in the presence 
of molecular oxygen; while the second is oxygen sensitive nitroreductase and it 
only works in extreme hypoxic area [36]. When there is a tumor, there is a hypoxia 
area and the concentration of the oxygen sensitive NTRs is getting higher. Due to 
its own characteristic, oxygen sensitive NTRs are of particular significance to the 
design of hypoxia sensitive fluorescent imaging agents [37]. 
In 1983, Olive and Durand found out the use of nitroaromatics for hypoxia imaging 
so they reported a family of 4 nitrofurans 3-6 (Figure 1-8). 
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Figure 1-8: fluorescence sensors based on nitrofuran 
They treated those 4 compounds into Chinese hamster V79 cells and observed their 
fluorescence change (Figure 1-9), because they found the mean cellular 
fluorescence can be used to predict the survival of single-cells, regardless of time 
of exposure or concentration of those compounds. 
 
Figure 1-9: Fluorescence intensity change of 4 sensors treated in cells (left) and 
the surviving test of those 4 compounds (right).  
The figure above showed the fluorescence change for those four compounds when 
the Chinese hamster V79 cells was exposed to each compound. Compound 3 
showed the greatest fluorescence intensity (on the left) and the least toxicity (on 
the right) among four compounds. 
From the conclusion, compound 3 could be used to estimate the fraction of hypoxic 
cells in multicellular and also they found that the fluorescence intensity of 3 was 
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highly responsive to cell oxygen concentration. All these results show that 
nitroheterocycles can be used as hypoxia sensors and the potential application of 
nitrofurans as fluorescent hypoxic cell markers [38]. 
The presence of hypoxia cause the bioactivity of nitroreductase to show a higher 
level. And under the hypoxic environment, nitro groups of compounds can be 
reudced to amino grouos by NTR. A lot of fluorescent probes have been made for 
hypoxia detection, however most of them are excited by one photon (with less than 
500 nm emission wavelength), and this property has limited the applications for 
the probes. Therefore, it is important to develop a new probe for monitoring NTR 
for detecting the occurrence and progress of tumors. Zhan Rong Liu and Co. 
workers synthesized a novel two-photon (TP) fluorescence turn on NTR probe 
compound 7 as a new TP fluorescent probe for sensing and imaging NTR, which 
used compound 8 including an optically tunable hydroxyl group as the 
fluorescence marker, and use p-nitrobenzyl moiety as the recognition position for 
NTR. When it treated with NTR under the NADPH (Figure 1-10), the nitro group 
would be reduced to the amino group, after the 1,6-rearrangement-elimination 
reaction to release compound 8 [39]. 
 
Figure 1-10: The TP fluorescence turn-on NTR probe compound 7 and how it 
reacts with NTR. 
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Figure 1-11: The fluorescence response of the compound 7 to NTR at different 
concentration in PBS (pH 7.4, 5% DMSO). 
The experiment was conducted by treating the compound 7 (5 μM) with NTR (0-
4.0 μg/mL) in the presence of NADH, and here was the emission spectrums for 
this reaction (Figure 1-11). As we can see from the figure, compound 7 was non-
fluorescent at beginning, once the NTR was treated in the presence of NADH, 
there was a very obvious increasing in fluorescence intensity at 510 nm. This result 
showed that the compound 7 had a very high sensitivity for NTR. 
In the cell experiment, the compound 7 was injected into HeLa cells, and the 
fluorescence images of the reaction were recorded at different oxygen 
concentrations. 
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Figure 1-12: (A) Fluorescence imaging of compound 7 with NTR in the living 
HeLa cells under normoxic (20% O2) and different hypoxic (15%, 10%, 5%, and 
1% O2) conditions. (B) Imagines of one-photon fluorescence intensity change of 
Hela cells. (C) Imagines of two-photon fluorescence intensity change of Hela cells. 
As compound 8 was a powerful two-photon dye, so they treated the compound for 
imaging NTR in the living HeLa cells by one-photon and two-photon modes. In 
the Figure 1-12, compound 7 was treated in cells under 20 % of oxygen and it did 
not show any fluorescence signal (f and p). Then they switched the compound 7 in 
HeLa cells to different hypoxic condition (from 15 % to 1 %). With the oxygen 
concentration decreased, the fluorescence signal increased gradually as showed in 
figure B. C. This results showed that compound 7 was able to detect NTR in cells 
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in both one photon and two photon modes. And compound 7 was more sensitive 
when it was in two photon mode. 
 
The recent development of ratiometric fluorescent sensor for hypoxia is the 
synthesis of naphthalimide sensor, which based on a p-nitrobenzyl functional 
group connected to the naphthalimide fluorophore through a carbamate linker [40]. 
This kind of nitro reductase based fluorescent sensor was designed by setting nitro 
recognition groups in the fluorophore, using the endogenous NADPH contained in 
the biological system as electron donor, and the electron withdrawing group nitro 
group of the sensor is reduced to the electron donating group amino group to form 
the 4-amino naphthalimide derivative by the presence of NTR. So that the sensor 
molecules internal charge transfer and lead to the change in optical signals with an 
obvious blue fluorescence to green fluorescence shift, and thus to achieve the 
detection of nitroredutase. 
 
Figure 1-13: fluorescence spectrum of compound 9 (10 μM) in PBS with 1% 
DMSO treated with NTR (10 μg/mL) with excitation wavelength of 410 nm. Inset: 
the emission ratio (F550/F475) verse time. 
 
In the fluorescence experiments of compound 9 with NTR (Figure 1-13), the 
compound 9 was injected into Escherichia coli and reacted with NTR. The 
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experimental results showed that the signal intensity decreases at 475 nm in 10 
minutes with the signal at 550 nm increased, and 80% of the compound 9 was 
converted to compound 10. The fluorescence signal of the reaction also undergoes 
a great change in the reaction process from blue to green. 
 
Figure 1-14: Mechanism of compound 9 when treated with NTR. 
 
The development of the compound 9 indicates that a selective ratiometric 
fluorescent probe has been successfully made and its color change in the solution 
also illustrated that the compound 9 can be used as an NTR fluorescent probe. 
Another example is that Ma et al. used resorufin as the fluorophore and conjugated 
5-nitrofuran and 5-nitrothiophene into the resorufin as recognition groups of NTR 
to develop two sensitive turn-on nitroreductase optical sensors 11 and 12 [41]. The 
reason they chose resorufin as fluorophore is that resorufin has a relative long 
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analytical fluorescence wavelength, excellent water solubility and its fluorescence 
can be quenched by substitution of its 7-hydroxy functional group.  
 
Figure 1-15: The resorufin based fluorescence probes compound 11 and 
compound 12. 
 
When under the environment of NADPH, the nitro groups of 11 and 12 can be 
reduced by NTR to form hydroxylamine or amino groups and subsequently 1,6-
rearrangement and elimination reactions to release resorufin and bright the 
fluorescence (Figure 1-16). The color change from colorless to pink.  
 
Figure 1-16: The mechanism of compound 11 reacted with NTR. Insert, the color 
of compound 11 and compound 13 with naked eyes. 
 
From the research, these sensors showed no toxic to other endogenous substances 
in the cells, according to that, a highly selective and highly sensitive method for 
the detection of NTR in cells was constructed. Meanwhile, people can also visually 
examine NTR and hypoxia cells based on the color change.  
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Figure 1-17: Fluorescence emission spectrum of compound 11 (5 μM) (a) before 
and (b) after reaction with NTR (0.20 μg/mL) in the presence of 500 μM NADH at 
37 °C for 30 min. Insert: The color and fluorescence changes of compound 11 
before and after the reaction. 
 
The spectroscopic response of compound 11 to NTR was showed in Figure 1-17. 
Compound 11 had no fluorescence emission at 585 nm, however, after the reaction 
with NTR, the fluorescence intensity had a 100 fold enhancement, and achieved a 
great fluorescence colour change from no fluorescence to red fluorescence. The 
result of the fluorescence spectrum from the reaction system was similar to those 
of resorufin [42] [43]. This result can also evident that the NTR causes the release 
of resorufin functional group. Compound 12 had the silimar selectivity to NTR but 
it had a higher sensitivity to NTR. Since it can quantitatively determine the 
concentration of NTR produced by Escherichia coli, compound could be the first 
probe which can quantitative determine the NTR of cells for real time. 
 
In most nitro-fluorescent probes, the nitro group is not directly attached to the 
fluorophore as an NTR recognition factor, most of which is indirectly connected 
to the fluorophore via an alkyl bridge. The probe that the nitro group is directly 
attached to the fluorophore is difficult to synthesize. However, in 2008, Qian [44] 
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and co-workers report about this new fluorescent sensors for NTR with a nitro 
group directly connect to the fluorophore (Figure 1-18). According to their reports, 
nitro can not only act as a fluorescence quencher, but also help to enhance 
fluorescence. 
 
Figure 1-18: The new hypoxia sensors while nitro groups directly connect to 
fluorophore. 
 
In their studies, they synthesised several compounds with nitro groups directly 
connected. First, they tested the fluorescence of the various compounds in a 
methanol solution. The result showed that compound 14 and 15 had very high 
fluorescence intensity while the rest compounds showed very weak fluorescence 
intensity (Figure 1-19).  
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Figure 1-19: The emission spectrum of compound 14 to 19 with the concentration 
of 10−5 mol / L in methanol. 
 
 
Among them, the nitro group of compound 14 was attached to the benzoimidazole 
ring and the nitro group of compound 15 was attached to the naphthalene ring. 
In general, nitro group usually worked as fluorescence quencher because it is an 
electron withdrawing group and reduced the conjugation of the compound to 
quench the fluorescence. In order to explain the high fluorescence intensity of 
compound 14, they designed an infrared experiment to prove the nitro group of 
compound 14 was highly conjugated with the compound. Since the nitro group 
increased the conjugation of the compound, it can improve the fluorescence as an 
electron acceptor. 
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Table 1-1: Spectra data of compound 14, 19, 18 and 16 
AAS Peak area of the anti-stretching vibration of nitro groups  
AS  Peak area of the stretching vibration of the nitro groups  
A0  Peak area of the stretching vibration of the C=O group of the corresponding 
compounds 
 
 
While the nitro group of compound 14 was reduced to amino group, which means 
the compound 14 converted to compound 17, the fluorescence had been quenched. 
On the other hand, the nitro group of compound 18 was worked as fluorescence 
quencher. There was no fluorescence of compound 18, when it was reduced to 
amino group, which means compound 18 had changed to compound 15, the 
fluorescence had increased. 
In addition, they modified the compound 14 and finally yield the compound 20 
 28 
 
                    
Figure 1-20: The structure of compound 20 and the emission spectrums of 
compound 20 in V79 379A Chinese hamster cells under different oxygen 
concentration. 
 
According to the cell experiment, they treated compound 20 in V79 379A Chinese 
hamster cells under a hypoxia environment and a normoxic environment to 
observe the fluorescence change over time. After 4.5 hr, there was a large 
fluorescence enhancement for compound 20 under normoxic environment (Figure 
1-20). By comparing the sensitivity of compound 14 and 20, they found that 
compound 20 showed a higher fluorescence intensity than compound 14 because 
the introduction of the methlpierazine functional group had improved the 
hydrophilicity and the solubility in cell culture media, thereby improving cell 
uptake. 
 
Another turn-on fluorescence probe for NTR is synthesised by Shao, Li and co-
workers [45]. They used a quaternized 4-pyridinyl-substituted fluorophore to 
increase the water solubility and also to increase the cells permeability. The 
fluorophore was conjugated to 5-nitrofuran to form a novel fluorescence probe 
compound 21 (Figure 1-21). 
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Figure 1-21: The novel fluorescence probe compound 21 and the mechanism when 
it reacts with NTR. 
 
 
In their studies, compound 21 showed a very weak fluorescence signal because of 
the photo-induced electron transfer (PET) process [46] [47] [48]. By reacting the 
compound 21 with NTR in the presence of NADH, the nitro group was reduced to 
the amino group, and after the electron transfer, followed by a 1,6-rearrangement 
and elimination reaction the furan moiety was eliminated and finally release the 
fluorescent group compound 22, which showed a fluorescence change from no 
fluorescence to green fluorescence. 
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Figure 1-22: The fluorescence intensity change of compound 21 (5 µM) with 
different concentration of NTR (0-5 µg mL-1). Insert: fluorescence photograph of 
compound 21 with NTR. 
 
 
In the fluorescence emission spectrum of compound 21 (Figure 1-22), there was 
no fluorescence for compound 21 when none NTR was treated while when treated 
NTR with the compound 21, there was a dramatic increase of fluorescence 
intensity at 520 nm with a very clear green fluorescence can be observed. This not 
only showed that the compound 21 can react as a hypoxia fluorescence probe for 
NTR, but also indicated the reaction rate of compound 21 with NTR increaseed as 
the concentration of NTR increased. 
 
The last example was a series of compounds reported by Feng [49]. They had 
developed an effective sensor which allows optical detection of NTR for in vivo 
imaging. These compounds were based on cyanine conjugates with nitro aromatic 
groups showed on Figure 1-23. 
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Figure 1-23: Nitro aryl–cyanine conjugates compound 23, 24, 25, 26 and 27. 
 
Figure 1-24: The fluorescence emission spectrum of compound 23-27 reacted with 
NTR. 
 
In the NTR response experiment (Figure 1-24), they treated those 5 compounds 
with NTR and observed the fluorescence intensity change for each compound. 
Figure. As we can see from the spectrum, compound 24 – 27 did not show any 
significant change in the fluorescence, while a dramatic enhancement of about 
110-fold in fluorescence intensity signal was observed for compound 23. 
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Compound 23 was used as tumor hypoxia sensor for NTR from this spectrum. And 
an in vitro imaging of hypoxic A549 cells with compound 23 was also conducted 
(Figure 1-25). The part (a) was the fluorescence imaging of an A549 tumor mode 
in a mice, the tumor was in the top right of the mice. And the part (b) was the 
fluorescence imagines of the tumor mode when treated with compound 23, as we 
can see in the figure, the fluorescence signal showed up once the compound 23 
was injected, and the fluorescence signal can be observed increased during time 
with naked eyes. Part (c) was the average fluorescence intensity of the tumor 
during time. The fluorescence reached to the peak at 70 s and stay constantly for a 
long while. This example demonstrated the ability of compound 23 to be an in 
cellulo imaging agent for hypoxia. 
 
Figure 1-25: In vivo fluorescence imaging of an A549 tumor mode (a) before and 
(b) after injecting compound 23. (c) The fluorescence intensity time-dependent 
experiment of compound 23 in solution (black) and when it was injected  to the 
tumor region (red) from 0 to 180 seconds. (Reproduced from J. Am. Chem. Soc., 
2015, 137, 6407–6416. r 2015 American Chemical Society). 
 
We have described the characteristics of cancer, introduced the nature of tumor 
hypoxia and the methods for tumor hypoxia detection. Also we have cited a lot of 
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examples of fluorescence probes for the detection of tumor hypoxia. The next 
section will be the introduction of the thesis research objectives. 
 
1.6 Research Objectives 
 
Tumor hypoxia, where the oxygen concentration become less than normal, can 
result in reductive stress where the concentration of many reducing species such 
as reduced glutathione, NADPH and many oxidoreductases increase rapidly. 
Among them, oxygen sensitive nitroreductase is a critial marker for reductive 
stress as it can selectively reduce the nitro group of compounds to an amino group. 
This feature has already been used in both prodrug strategies and in approaches 
for tumor hypoxia detection. The study of the fluorescence probes for NTR in 
hypoxic environment is always hampered and limited, and the fluorescence probes 
are only studied in recent years. Many other  research groups [50] [51] [52]have 
already reported their fluorescence probes for tumor hypoxia detection while most 
of them taking nitrothiophene, nitrofuran  or nitrobenzene as the nitro aromatic 
functional groups to recognize NTR in tumor. However, another nitro aromatic 
substrate that is seldom mentioned in the synthesis of fluorescence probes, 2-
nitroimidazole, is often used in prodrug strategies. It appears that, to date, 2-
nitroimidazoles have been neglected as potential markers for fluorescence NTR 
recognition. Therefore, the thesis aims to evaluate 2-nitroimidazoles as markers in 
fluorescence detection of NTR and compare its sensitivity and selectivity to other 
more common nitroaromatics. 
In the compound design stage, we envisioned the use of amino naphthalic 
anhydride as a fluorophore with 2-nitroimidazole connected to the fluorescent 
group through carbamate linker would furnish new fluorescent probes compound 
28 and compound 29 (Figure 1-26). 
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Figure 1-26: The novel fluorescence probes compound 28 and compound 29 of 
this thesis. 
 
In our hypothesis, the nitro groups of this two compounds will be reduced to amino 
group with NTR in cells and the rearrangement reaction will lead to the cleavage 
of imidazole moiety and carbamate linker, finally it will release the amino 
naphthalimide as fluorophore to modulate fluorescence characteristics (Figure 
1-27). 
 
Figure 1-27: Mechanism of the novel fluorescence probe reacted with NTR. 
 
After those two fluorescence probes have been made, our next object is to vary 
different nitroaromatic triggers as NTR recognition targets to increase the 
sensitivity to NTR and compare the abilities of various nitroaromatics such as 
nitrofuran, nitrobenzene and nitrothiophene to act as markers for reductive stress. 
(Figure 1-28). 
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Figure 1-28: Novel compounds for sensitivity improvement 
 
Finally, once the most sensitive compound to NTR has been identified, we will 
modify the compound to make it amenable to bioconjugation and also allow site 
selective uptake of the sensor to enable reductive stress measurements at organelle 
specific locations.  
 
Figure 1-29: Novel compounds for bioconjugation and mitochondrial targeting. 
 
In this thesis, we will report the synthesis of the novel sensors and a discussion of 
the photophysical characteristics in addition to the spectroscopic response to NTR. 
In some cases, preliminary cellular experiments have been carried out. Finally, 
based on our findings we will propose some improvements and modifications to 
ensure the most selective and sensitive fluorescent sensors for NTR. 
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Chapter 2 : 2-Nitroimidazole-naphthalimide 
conjugates as fluorescent sensors for 
nitroreductase. 
2.1 Introduction 
 
Since the first reported example of a fluorescent ratiometric probe in solid tumors 
in 2011 [53], improvements have been made in fluorescence detection of tumor 
hypoxia in vivo. The development of fluorescent probes for NTR has already 
become a burgeoning area of research interest. With the discussion in Chapter 1, 
we knew this kind of ratiometric probes require a nitroaromatic trigger to initiate 
the reduction reaction in cells with NTR and finally release the fluorophore to shift 
the fluorescence signal. In recent years, the research on ratiomatic triggers was 
limited to nitrobenzene, nitrofuran or nitrothiophene due to their relative ease of 
reduction. However, there is one compound that has not be used as nitroaromatic 
trigger despite it was widely used in the development of bioreductive prodrugs. 
The compounds with nitroimidazole as the parent nucleus have a very important 
role in the study of hypoxia imaging agents due to their ability of hypoxia targeting. 
And the tumor hypoxia targeting of nitroimidazoles is mainly based on the 
reduction susceptibility of nitroimidazole at different oxygen concentrations. In 
the cells with normal oxygen content, the nitro groups of these compounds 
generate free radical anions under the reaction of xanthine oxidase and rapidly 
reoxide to nitro group to diffuse out of the cells. While under hypoxic conditions, 
the free radicals are further treated with nitro reductase and the products bind to 
the intracellular component and remains in the cell [11]. The position of the nitro 
group on the imidazole ring mainly includes 2-nitroimidazole (2-N), 4-
nitroimidazole (4-N), 5-nitroimidazole (5-N). Among them, 2-nitroimidazole has 
the highest reduction potential, which means that it is most likely to be reduced in 
an oxygen-free environment. 
The objective of the research presented in this Chapter was developing a series of 
fluorescence detection probes based on naphthalimide and 2-nitroimidazole 
functional group, compound 28 and compound 29. Compound 28 and compound 
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29 were two new fluorescently responsive NTR sensors that we envisaged a 2-
nitroimidazole group coupled to a naphthalimide fluorophore through a carbamate 
linker so that they may afford ratiometric probes with sensitivity to NTR. 
 
Scheme 2-1: Synthesis of novel fluorescence sensors 
 
The purpose of designing these compounds was to develop sensitive fluorescent 
probes for cellular reductive stress. As we thought 2-nitroimidazole group (36) 
would have a great performance in a reductive environment by reducing the nitro 
group to amino group through NTR in cells consider its high reductive potential. 
In the design of these compounds, carbamate linker was used to connect the 
fluorophore and the nitroaromatic trigger, because carbamate linker could change 
the functional group attached to the fluorophore from electron donating group to 
electron withdrawing group, which can change the fluorescence signal. We 
envisaged that when treated with NTR in cells, both compound 28 and compound 
29 would be reduced and given rise to a fragmentation of the parent molecule and 
release of the well-known amino-1,8-naphthalimide fluorophores as shown below 
of scheme 2-2. It was expected that the conversion of the electron-withdrawing 
carbamate linker to the electron-donating amino functional group would lead to 
significant modulation of their optical properties and lead to a fluorescence shift 
visible to the naked eye. 
 
Scheme 2-2: Reaction mechanism of novel fluorescence sensors 
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The overall aim of the work presented in this chapter is to explore the various 
properties of the compound 28 and 29. Firstly, there will be a brief description of 
the synthesis and characterization of each compound. This is followed by a 
discussion of the photophysical properties of these compounds. Then comes the 
discussion of the response of the probes to the enzyme NTR. Finally, preliminary 
biological studies will be described, cellular uptake and localization as well as 
cellular toxicity studies. 
 
Figure 2-1: Two novel fluorescence sensors 
 
 
2.2 Synthesis 
2.2.1 Synthesis of compound 36 
 
The synthesis of compound 29 was achieved using an intermediate in the synthetic 
pathway of 2-nitro-imidazole (36) as outlined in scheme 2-3 and scheme 2-4. Both 
compound 28 and compound 29 were synthesized by reaction with compound 36. 
Therefore, to successfully synthesise compound 36 was the first step in the whole 
scheme. In this section, we discussed the conventional synthesis procedure 
(Scheme 2-3) of compound 36 and compared it with novel synthetic methods 
(Scheme 2-4), followed by identification of the intermediate product during the 
reaction to determine the progress of the reaction. 
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Scheme 2-3: The conventional synthesis procedure of compound 36. 
 
For the conventional synthesis of compound 36 shown in Scheme 2-3 [54], 
sarcosine methyl ester hydrochloride was chosen as starting material, which was 
reacted with NaH in ethyl formate to have the di-substitution reaction. The mixture 
was acidified and heated to afford elimination of a single aldehyde. Then the 
mixture had a ring forming reaction with cyanamide to form compound 37. 
Compound 37 was going through an oxidation reaction and an ester reduction 
reaction to form the final product compound 36.   
If we turn back and have a look at the above reaction, we can see many 
shortcomings for this reaction. First of all, the raw material was sarcosine methyl 
ester hydrochloride, which was not very soluble in ethyl formate, and this largely 
restricted the yield of the reaction (35 % yield). Second, sodium hydride we used 
was 60 % present in mineral oil, so the amount required was very large and the 
reaction produced a sticky solid that is difficult to handle. More importantly, the 
hydrogen produced during the process is dangerous. The next shortcoming was 
that the reaction time was quite long. Finally, the post treatment of the reaction 
was very complicated (evaporated 7/8 of the solvent and then titration to adjust the 
reaction conditions). 
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Scheme 2-4: The novel synthesis procedure of compound 36. 
 
Therefore, we had improved the reaction based on the shortcomings. We replaced 
some reactants and changed the reaction conditions and eventually formed the 
following reaction process (scheme 2-4): We used sarcosine ethyl ester 
hydrochloride as starting material, reacted with potassium tert-butoxide in ethyl 
formate at room temperature to have the di-substitution reaction. Then the mixture 
had elimination reaction with concentrated HCl and had the ring close reaction 
with ethylene glycol. After that used cyanamide to form compound 39. Similar to 
the conventional synthesis, compound 39 had a diazonium reaction through 
sodium nitrite to compound 40 and the ester function group of compound 40 was 
reduced to carboxyl group to form compound 41. Finally, compound 41 was 
reduced by sodium borohydride to form compound 36. 
With two different procedure in hand, we had a comparison of this two procedures. 
Instead of using sarcosine methyl ester hydrochloride, we chose sarcosine ethyl 
ester hydrochloride as our starting material in novel synthesis procedure because 
sarcosine ethyl ester hydrochloride was much more soluble in ethyl formate. It 
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only took 3 hr to complete the first step of this procedure while it required 
overnight reacting with sarcosine methyl ester hydrochloride, which saved much 
more time for this reaction. And the new method was using potassium tert-
butoxide as a strong base while the sodium hydride was used in the conventional 
one. The advantage of doing so was that it does not produce gas, made the 
experiment safer, and it does not produce sticky solid, made the reaction easier to 
handle. Then, in the conventional synthetic method, the final compound 36 was 
obtained by direct reduction of its ester form, and the yield was only 28 %. While 
in the novel synthetic method, we reduced the ester to acid first, then yielded the 
final product compound 36 by reducing the acid. Although the number of reaction 
step was increased, the overall yield was improved (50.1 % yield). Last but not 
least, the new experimental program does not require a change of solvent during 
the reaction, sequence thereby simplifying the reaction procedure. 
By comparison, we knew that the new method shown in scheme 2-4 can effectively 
improve the reaction yield and simplify the reaction step, making the experiment 
safer and faster. Therefore, for the synthesis of compound 36, we were more 
inclined to use the new method. After that, we detected the synthesized compounds 
from the new method according to characterisation. 
Since the first and the second step in scheme 2-4 was inseparable, our detection 
was started from compound 39.  
Compound 39 was characterised by 1H NMR, melting point analysis, mass 
spectrometry, 13C NMR and IR spectroscopy. The 1H NMR spectrum is shown in 
figure 2-2. Assignment of the peaks was achieved by H-H COSY and C-H COSY 
analysis.  
In the Figure 2-2, we can clearly see 5 signals which perfectly matched the H of 
compound 39. The peak at 7.28 ppm which integrated as 1 H represents the H in 
the imidazole group, and the signal at 6.189 ppm stands for the NH2 of compound 
39 because this peak was singlet and integrated as 2. Peaks at 4.15 ppm and 1.24 
ppm represent the ethyl group of compound 39, and at last, peak at 3.52 ppm stands 
for the CH3 group on the N. Also from the MS, the formula of compound 39 was 
C7H11O2N3, the mass we calculated was 169.0851 while with the machine the 
tested result was 169.0851. the PPM was 0.01, which perfectly matched the result 
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calculated. Therefore, with the 1H NMR and MS, we can admit that compound 39 
was made successfully. 
 
 
 
 
Figure 2-2: The 1H NMR spectrum of compound 39 (500 MHz, DMSO-d6) 
 
 
Figure 2-3: The 1H NMR spectrum of compound 40 (500 MHz, DMSO-d6) 
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Compound 40 was characterised by 1H NMR, melting point analysis, mass 
spectrometry, 13C NMR and IR spectroscopy. The 1H NMR spectrum is shown in 
figure 2-3. In this spectrum, peak at 7.8 ppm stands for the H of the imidazole 
group. The chemical shift was moved to left side compared with the H in the same 
position of compound 39 which had 7.28 ppm chemical shift. This was because 
the amino group was changed to nitro group whereas it converted an electron 
donating group to an electron withdrawing group and decreased the electron 
density to deshield the H. Also the signal at 6.19 ppm which represent the NH2 
group disappeared in the spectrum of compound 66, this proved the compound 40 
was successfully made from compound 39. Finally, peaks at 4.34 ppm and 1.32 
ppm stand for the ethyl group just similar to compound 39. In compared with this 
two spectrums, we can see compound 39 was made successfully and compound 
40 was changed from compound 39 by switching the amino group to nitro group. 
 
 
Figure 2-4: The 1H NMR spectrum of compound 41 (500 MHz, DMSO-d6) 
 
After the oxidising of the amino group to nitro group, compound 40 was reduced 
to compound 41. The ethyl group was disappeared so we cannot see the signals at 
4.34 ppm or 1.32 ppm from figure 2-4. However the signal at 7.73 ppm and 4.19 
ppm stand for the H in imidazole and the CH3 group on the imidazole group 
separately was still the same as figure 2-3, which means the main structure of 
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compound 40 was not changed, the only change was the ester group was reduced 
to a carboxyl group. 
 
 
Figure 2-5: The 1H NMR spectrum of compound 36 (500 MHz, DMSO-d6) 
 
Compound 39 was characterised by 1H NMR, melting point analysis, mass 
spectrometry, 13C NMR and IR spectroscopy. The 1H NMR spectrum is shown in 
Figure 2-5. Assignment of the peaks was achieved by H-H COSY and C-H COSY 
analysis. Successful formation of compound 39 was also evident from accurate 
mass spectrometry. 
Compound 41 was reduced to compound 36, we can see in the spectrum, two new 
signals appeared, peak at 5.48 ppm integrated as 1 represents the OH signal and 
peak at 4.55 ppm integrated as 2 represents the CH2 group. The chemical shift at 
7.12 ppm stands for the H in the imidazole was shifted highfield, and the signal at 
3.92 ppm stands for the CH3 group also shifted to Highfield compared to 
compound 41. The reason was the carboxyl group was electron withdrawing group, 
when it converted to an alcohol group, it was changed to an electron donating 
group compared to a carboxyl group. This increase the electron density and caused 
the shield of the hydrogen and finally, the peak shifted to left. 
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2.2.2 Synthesis of compound 29 
 
 
Scheme 2-5: The synthesis of compound 29 
 
With the compound 36 in hand, our next step was to synthesis the two different 
fluorophores and connect the two fluorophores with compound 36 through a 
carbamate linker. 
In order to synthesis compound 29, 3-nitro-1,8-naphthalic anhydride and butyl 
amine were heated under microwave irradiation to yield compound 42. Then 
compound 42 had the reduction, making the nitro group to amino group to form a 
bright yellow solid compound 43 at 98% yield. Finally, to get the final product, 
compound 43 was reacted with phosgene in the presence of DMAP first and then 
reacted with compound 36 to yield a beige solid compound 29 at 63% yield.  
In order to make sure all steps were successfully proceeded, we compared the 1H 
NMR spectrums of each intermediate. 
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Figure 2-6: The 1H NMR spectrum of compound 42 (500 MHz, DMSO-d6) 
 
From the spectrum of compound 42 in figure 2-6, we can clearly see that there 
were 9 signals which represent 9 kinds of H of compound 42. Peaks from 7 ppm 
to 10 ppm were the aromatic H and peaks between 1 and 5 ppm were the aliphatic 
H.  Peak at 0.93 ppm integrated 3 stands for the H1 and peaks at 1.34 ppm and 
1.62 ppm which both integrated 2 represented H2 and H3 respectively. The 
chemical shift of H4 was 4.03 ppm, which shifted to downfield compared to the 
rest CH2 groups. The reason was that this CH2 group was attached to two carbonyl 
groups which were electron withdrawing groups, and those carbonyl groups 
decreased the electron density of H4, caused de-shield and finally made the H4 
move to down field. The peak at 8.89 ppm was a singlet, means this H did not 
attach with other H, so peak at 8.89 ppm stands for H9. H5 was attached to one H 
and it was closed to a carbonyl group, therefore the signal of H5 should be 
downshield and doublet, also known as 9.42 ppm. H6, H7, and H8 were confirmed 
by H-H COSY and C-H COSY analysis. 
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Figure 2-7: The 1H NMR spectrum of compound 43 (500 MHz, DMSO-d6) 
 
Compared with compound 42, there was very little change from figure 2-7. First 
of all, the aliphatic H did not change, it stayed with same chemical shift. Then, 
there was one new signal shown up. Peak at 6.04 ppm integrated 2 stands for the 
NH2 group. Last, all the aromatic H had shifted to high field because once the nitro 
group changed to amino group, the electron withdrawing group had changed to 
electron donating group, this change increased the electron density of the aromatic 
ring and caused shield of the proton. According to the above description, we can 
be sure that compound 43 had been made successfully and was ready for the next 
synthesis. 
 
Figure 2-8: The 1H NMR spectrum of compound 29 (500 MHz, CDCl3) 
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Compound 29 was characterised by 1H NMR, melting point analysis, mass 
spectrometry, 13C NMR and IR spectroscopy. The 1H NMR spectrum is shown in 
figure 2-8. Assignment of the peaks was achieved by H-H COSY and C-H COSY 
analysis.  
As we see in the spectrum of figure 2-8, peaks at 7 ppm to 9 ppm represent the 
aromatic peaks and peaks between 1 ppm and 6 ppm were aliphatic H. There were 
13 different kinds of H in compound 29, if we compared it with compound 43, 
there was a broad peak shown up at 8.56 ppm which stands for the NH of 
compound 29 and the chemical shift moved downfield because the NH group was 
connected with ester group which was electron withdrawing group, causing 
deshield to shift the peak to down field. There were 6 aromatic H while compound 
43 only had 5, so the extra aromatic H stands for the H in imidazole functional 
group. If we combined those two spectrums of compound 43 and compound 29, 
we can find out that the chemical shift of butyl group of compound 43 was much 
similar as the chemical shift of butyl group of compound 29, therefore the peaks 
at 0.94 ppm, 1.44 ppm, 1.71 ppm and 4.16 ppm stand for the butyl group of 
compound 29. The peak at 4.1 ppm integrated 3 represents the CH3 group on the 
imidazole functional group. Finally, the peak at 5.32 ppm can only stand for the 
CH2 group beside the imidazole group, shifted to downfield because the electron 
withdrawing group ester group connected by. 
According to the comparation with the 1H NMR spectrum, we were very confident 
that compound 29 had been produced. Our next aim was to synthesis the other 
fluorescence sensor compound 28. 
 
2.2.3 Synthesis of compound 28 
 
The procedure to synthesis compound 28 (Scheme 2-6) was just the same as 
compound 29, 4-nitro-1,8-naphthalic anhydride was chosen as the starting material. 
After the reaction with butylamine, it went through a reduction reaction of the nitro 
group to amino group. Then connected the naphthylamide with the trigger through 
the carbamate linker to yield the product compound 28. 
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Scheme 2-6: The synthesis of compound 28 
 
Compound 28 was characterised by 1H NMR, melting point analysis, mass 
spectrometry, 13C NMR and IR spectroscopy. The 1H NMR spectrum is shown in 
figure 2-9. Assignment of the peaks was achieved by H-H COSY and C-H COSY 
analysis. Compound 28 had 13 different kinds of H, and the only different between 
compound 28 and compound 29 was the substitution potion. Therefore, the 
different between this two compounds on the spectrums was the chemical shift and 
the multiple of aromatic H. In the spectrum of compound 28, there was only one 
singlet aromatic H which represents the H on imidazole group while there were 
two singlet peaks in compound 29. In addition of this, there was little different 
between compound 28 and compound 29. The peak at 0.92 ppm, 1.35 ppm, 1.63 
ppm and 4.06 ppm represent the butyl group of compound 28. The peak at 4.04 
ppm integrated 3 stands for the CH3 group on the imidazole group and peak at 5.39 
ppm stands for the CH2 group on the imidazole group. 
Due to the overall similarity of this two spectrums and the difference in aromatic 
region, we can be sure the compound 28 had been made successfully. 
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Figure 2-9: The 1H NMR spectrum of compound 28 (500 MHz, DMSO-d6) 
 
Through the discussion of the synthesis procedure and the analysis of the 1H NMR 
spectra, we had successfully synthesized the compounds. However we did not 
know too much about the photophysical properties of this compounds while the 
fluorescence properties of this compounds were important for exploring them as 
hypoxia fluorescent sensors. Therefore, our next aim was to detect the 
photophysical properties of these compounds. 
 
2.3 Photophysical characterisation of compound 28 and 
compound 29 
2.3.1 Absorption and emission spectra of compound 28 and 
compound 29 
The absorption and emission spectra of compound 29 and compound 28, recorded 
at pH 7.4 in 10 mM phosphate buffer with 0.5% DMSO as co-solvent were shown 
in below. 
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Figure 2-10: The UV/Visible spectra of compound 28 and compound 29 and their 
reference fluorophores. 28 (red), 29 (blue), 45 (purple) and 43 (green). 
 
 
The absorption spectrum of compound 28 (figure 2-10) showed a max at ca. 360 
nm while compound 29 showed a max at ca. 345 nm with a broad shoulder centred 
at 390 nm. So we chose 345 nm as our excitation wavelength cause the absorption 
at 345 nm were relatively high for both compound 29 and compound 28. Therefore, 
the excitation (exc = 345 nm) compound 28 (Figure 2-11)showed rise to emission 
with max at 475 nm while compound 29 yielded emission spectrum (Figure 2-12) 
with max at 460 nm. The value of the max intensity of compound 29 was 3 fold 
less than that of compound 28 when treated with same concentration. One possible 
reason is the fluorescence intensity could be changed by the anion’s 
electronegativity and the fluorescence behaviour of compounds depending on their 
electronegativity [54]. We suggested compound 28 and compound 29 were treated 
with NTR in cells to make nitro group to amino group and then yield the 
corresponding amino-derivatives compound 45 and 43 thus causing significant 
shifting of spectral characteristics. Because of this, we also need to compare the 
photophysical characteristics of compound 28 and compound 29 with those of 
compound 45 and compound 43. 
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The absorption spectrum of compound 45  (Figure 2-10) showed a max at ca. 435 
nm while compound 43 showed max at ca. 345 nm and 410 nm (Figure 2-10). 
Emission from compound 45 (exc = 435 nm) showed a max at 550 nm while that 
of compound 43 (exc = 345 nm) showed a max at 590 nm, again demonstrating a 
lower level of emission when compared against the 4-substituted derivative. If we 
compare the emission spectrums of compound 28 and 45 we can see that the 
maxima peak signal was shifted about ca. 75 nm while that of compound 29 and 
43 was 130 nm but still with low emission intensity. This result is consistent with 
the previous observations of the absorption spectrums. 
 
 
Figure 2-11: The emission spectra of compound 28 (10 µM) and its fluorophore 
reference compound 45 in 10 mM phosphate buffer at pH 7.4 
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Figure 2-12: The emission spectra of compound 29 (10 µM) and its fluorophore 
reference compound 43 in 10 mM phosphate buffer at pH 7.4 
 
2.3.2 NTR Response  
Compound 29 not only shows lower absorption in UV/Visible spectrums than 
compound 28 but also shows lower intensity in the emission spectrums. So now 
we investigated their spectral properties when placed under reductive stress 
conditions by treatment with NTR (oxygen insensitive NTR expressed in E. coli). 
The emission spectrums were measured in PBS (pH 7.4, 10 Mm) with 0.5% 
DMSO as co-solvent in the presence of NADPH (50 µM, as a cofactor of NTR) at 
25 °C. 
When treated compound 28 with 0.5 µg NTR, we can see an emission spectrum 
with the intensity change during times (figure 2-13). The emission maximum at 
475 nm was decreased while the signal at 550 nm was a coherent increase, clearly 
visible to the naked eyes as a blue fluorescence to green fluorescence change in 
colour. After 20 mins, the fluorescence intensity at 550 nm was increased by more 
than 8-fold than before while the emission at 475 nm had decreased for 5-fold. The 
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colour changed from blue to green in fluorescence also proved the transformation 
from compound 28 to 45 while treated with NTR. 
 
Figure 2-13: Changes in the emission spectrum of compound 28 (10 µM) at 
various time points (0 - 25 mins) after addition of NTR (0.5 µg mL-1). Insert, 
pictures beside the spectrum were the colour change of compound 28 when treated 
with NTR. The blue fluorescence on the left represents the colour at the beginning 
when treated with NTR; the green fluorescence on the right represents the colour 
of the compound and NTR after 20 minutes of reaction. 
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Figure 2-14: Changes in the emission spectrum of compound 29 (10 µM) at 
various time points (0 - 25 mins) after addition of NTR (1 µg mL-1). 
 
Interestingly, compound 29 did not have the same result as compound 28, there 
was no fluorescence change when treated with NTR under the same conditions. 
The colour of compound 29 in the vial did not change after treating with NTR. 
Similar information can be seen on the emission spectrum of figure 2-14, we 
treated compound 29 with 0.5 μg of NTR in PBS, and the figure 2-14 here was 
emission spectrum with intensity change during time. Compound 29 had an 
emission maximum at 460 nm, and the emission intensity decreased slightly over 
time. Also a slight upward trend in emission intensity was observed at 590 nm. 
After 20 mins, the intensity of the signal at 460 nm decreased by 1/7, and the 
intensity of the signal at 590 nm increased by only 1/3. Although it cannot be said 
that the compound 29 does not react with the NTR at all, such a small change is 
difficult to detect. Visually, compound 29 showed blue fluorescence, but unlike 
compound 28, it did not react with NTR to become green fluorescence, further 
demonstrating that compound 29 was not reacted with NTR effectively. 
The emission spectra showed us the fluorescence intensity of compounds 28 and 
29 and it preliminary proved that compound 28 can react effectively with NTR 
undergoes fluorescence changes and also showed that the emission intensity of 
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compound 29 varies little when treated with NTR during time. Resulting in the 
inability to determine whether compound 29 reacts with NTR by photophysical 
methods. Next, we used various other methods to confirm the fragmentation 
pathway of compound 28 and 29. 
 
2.4 ESI-LCMS Study 
In order to further explore the change of compound 28 and 29 when treated with 
NTR in reductive stress condition, we also conducted a mass spectrometry to trace 
the reaction. 
 
Figure 2-15: Analytical LCMS traces of (a) compound 28, (b) compound 45 and 
(c)compound 28 after treatment with NTR (1µg/mL) in the presence of NADH (500 
µM); (0-100% acetonitrile over 20 min, 0.1% Formic Acid, λ = 254 nm); 
Calculated Mass of 1 [M+H]+ : 452.1565; Calculated Mass of 2 [M+H]+ : 
269.1285 
 
As we can see from the figure 2-15, the peak in (a) represents the signal of 28 
where the MS spectrum revealed peaks at m/z = 452.1535 and 474.1345 attributed 
to the [M + H]+ and [M + Na]+ ions of compound 28 respectively. The peak in (b) 
represents the signal of 45 where the MS spectrum revealed peaks at m/z = 269.13 
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and 307.08 attributed to the [M + H]+ and [M + K]+ ions of 50 respectively as 
reference. The peak in (c) was measured when compound 28 was treated with NTR 
and NADPH in PBS. Moreover, this peak revealed peaks at m/z = 269.13 and 
291.10 which showed the [M + H]+ and [M + Na]+ ions of 45. This result showed 
that when the compound 28 was added to the NTR, the signal of the original 
compound 28 disappeared and the signal of the compound 45 was detected. These 
three graphs fully illustrated that compound 28 can be quickly converted to its 
reference compound 45 when treated with NTR. 
However, there was no fluorescence change when compound 29 was treated with 
NTR under the same condition while ESI-LCMS only gave rise to peaks at m/z = 
452.15 and 474.13 attributed to the [M + H]+ and [M + Na]+ ions of the compound 
29, respectively. 
In conclusion, with the detection of mass spectrometry, compound 28 was 
confirmed to be converted to compound 45 in the presence of NTR, indicating that 
compound 28 has a very high level of reactivity to oxygen sensitive NTR in the 
presence of NADPH to reduce its nitro group and goes through a chain break to 
form compound 45 and finally shift the fluorescence single from blue to green. On 
the other hand, there were no signal of compound 43 was found in the reaction of 
compound 29 with NTR. And since the intensity of emission spectrum was not 
changed. We infer that compound 29 does not react effectively with NTR. 
 
2.5 Characteristic Detection of 28 
2.5.1 Sensitivity Study 
Considering the above results, we thought that substitution at the 4 -portion is the 
key element for this reaction, so we chose to concentrate our efforts on compound 
28. We also converted experiments to investigate the sensitivity of compound 28 
to the enzyme by releasing the fluorophore in the presence of different 
concentrations of NTR (0 – 5 µg mL-1). 
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Figure 2-16: Plots of the change in emission intensity at 545 nm as a function of 
time after treatment with various concentrations of NTR in the presence of NADH 
(50 µM). 
 
The same concentration of compound 28 was placed in 5 vials and different 
concentrations of NTR were added to each vials. Since we had determined that the 
reaction of compound 28 with NTR was fully capable of generating and formed 
compound 45, we had recorded the emission intensity at 545 nm during the 
reaction, which corresponds exactly to the concentration of the compound 45. And 
the higher the intensity represents the more formation of compound 45. The shorter 
the time to reach a certain intensity, the faster the reaction rates. 
From the figure 2-16 we can see that higher concentration of NTR can result in a 
faster increase in fluorescence intensity. As we increased the concentration of NTR 
the intensity goes higher and faster to reach the maximum value, which means 
more compound 28 had reacted with NTR when the concentration was increased 
and the more compound 28 was, the more it can help the reaction to proceed more 
quickly. When treated with 5 µg mL-1 of NTR, almost 90 % of compound 28 had 
transformed to compound 45 in 5 mins at 25 °C while it took almost 15 mins for 
the reaction to complete when the concentration of NTR was 0.5 µg mL-1. 
 59 
 
Moreover, the concentration of NTR from 0.5 µg mL-1 to 5 µg mL
-1 gave a linear 
response whereby increasing the concentration of NTR gave rise to a rapid 
fluoresce modulation. Finally, in the absence of no response was observed 
demonstrating the stability of compound 28 under the mimicked biological 
conditions. 
 
2.5.2 pH Study 
The next experiment was to measure the reaction of compound 28 to NTR at 
different pH. As shown in the figure 2-17, we set different pH values of the 
environment (pH = 5 – 9) in different vials and inserted compound 28 and NTR 
with same concentration. The result indicated that compound 28 showed the 
highest activity between pH = 6 and 7, which demonstrated the applicability of 
compound 28 to a biological environment whereby it was shown to perform best 
at pH values consistent with those found in biological media. 
 
Figure 2-17: Changes in the emission spectrum of compound 28 (10 µM) (λex 345 
nm) at various pH values 
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2.5.3 Selectivity Study 
Because of the diversity of substances in biological cells, our compound 28 was 
inevitable to be exposed to these biological interferents in cells. Therefore, the 
ability to effectively identify and eliminate the interference of these substances has 
become the primary problem. To this end we set an experiment to simulate the 
diversity of biological cells and we selected most of the representative substances 
(NaCl, CaCl2, MgCl2, glucose, H2O2, aspartic acid, lysine, serine, tyrosine and 
lysozyme) as interference items to detect the biological selectivity of the 
compound 28. We added the same concentration of compound 28 in each 
substance, and we measured the emission intensity at the same wavelength after 
20 mins. 
 
Figure 2-18: Changes in the emission spectrum of compound 28 (10 µM) (λex 345 
nm) upon addition of various biological interferants. 
 
From the result of figure 2-18, compound 28 displayed a high level of both stability 
and selectivity towards NTR over all of the other species tested. Its emission 
intensity was almost three times more than in other substances. When compound 
28 was in other substances inside, its material concentration is almost unchanged. 
In general, compound 28 exhibited a high stability and sensitivity in a simulated 
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biological tissue environment, moreover, it can find the target NTR very quickly 
under various interference and reduce the nitro group to amino group to release the 
fluorophore and finally shift the fluorescence. 
 
2.6 Enzyme Study  
2.6.1 Biological behaviour 
In the above experiments we have discussed the spectral characteristics and the 
sensitivity of bioreduction of compound 28, and the result was very positive. Our 
next test was to evaluate compound 28 as a biological probe for reductive stress in 
cells, to explore its ability to be internalised in target cells (These studies were 
conducted with the help of Dr. Sandra Bright carried out at TCD). Cellular 
environment was conducted in cervical cancer HeLa cells. We incubated live cells 
(0.5 × 105) with compound 28 (10 µM) at 37°C for 4 hrs (figure 2-19). Through 
the fluorescence confocal microscopy we obtained a clear result showing below. 
The compound 28 successfully attached to the cytoplasmic position within the 
cells, which emitted a strong blue fluorescence as an evidence of its presence in 
the cells. We also did the same experiment with its fluorophore group compound 
45. As a result, the compound 45 can also adhere to the cytoplasm of cells and 
emit a different but still strong fluorescence in the same environment. The rates of 
these compounds 28 and 45 get into the cells were also investigated by using flow 
cytometry in figure 2-20. The result indicated that both of them were shown to be 
rapidly taken up into cells and reaching their peak uptake within 15 mins and stay 
constant for a long while. 
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Figure 2-19: Cellular localisation of compound 28 and 45 in HeLa cells at 37°C 
 
 
 
Figure 2-20: Cellular uptake determined by flow cytometry 
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Figure 2-21: Cellular localisation at 4°C 
 
 
Figure 2-22: Passive diffusion and endocytosis determined by flow cytometry 
(Scale bar = 10 µm). 
 
In order to explore the way the compound 28 enters the cells, we also carried out 
the following experiments. We injected compound 28 and its reference 
fluorophore compound 45 into HeLa cells at 4 °C to see if the cell fluorescence 
signal generation. Experiments showed that at such a low temperature we can still 
observe the fluorescence signal generated by compound 28 and 45 (Figure 2-21). 
The experiment also proved that the way compound 28 was getting into the cells 
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should be passive diffusion (Figure 2-22), since the diffusion which needs ATP, is 
inhibited at this low temperature. In agreement with this, we treated the cells with 
the general endocytosis inhibitor dynasore, and then put compound 28 and 45 into 
the cells, the result showed no effect on the uptake of compound 28 or 45. 
Compound IC50 value 
(µM) 
28  >75 
29 6.5 
45  45.6 
43 35.3 
Table 2-1: Table summarising viability data of compounds 28, 29, 45 and 43 after 
treatment of HeLa cells for 24hrs (Scale bar = 10 µm). 
 
Cellular viability in the presence of 28, 29 and 45, 43 was also measured using an 
AlamarBlue assay (table 2-1). The result showed that the IC50 value of compound 
28 could not be measured and was observed without any cytotoxicity. And 
similarly, compound 45 had observed a modest IC50 value of 29 µM when cells 
were treated for 24 hrs. This showed that compound 28 showing no observed 
toxicity to the cells and the same as the released compound 45. While what 
interesting us was that compound 29 and 43 were shown to have increased toxicity 
with IC50 values of 7 µM and 35 µM respectively. Compound 29 was shown that 
it is not suitable for being developed as a probe for detecting hypoxia in cells, and 
the reason that its IC50 value is so low could be their structural similarities to the 
known anti-proliferative agent amonafide. 
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2.6.2 Ability of reduction in cells 
With the biological behaviour of these compounds characterised we next wished 
to evaluate their abilities to monitor reductive stress in cells. Before the cell 
experiment we had some adjustments to the experiment environment. We treated 
HeLa cells with NTR (1 µg mL-1) and its co-factor NADPH (0.5 M) before 
addition of compound 28 or 29 (10 µM) in order to mimic reductive stress on the 
cell population. 
 
Figure 2-23: Confocal laser scanning microscopy images of HeLa cells after 
treatment with compound 28, 45 and 28 (10µM) under reducing conditions. 
Nuclear imaging with red nuclear stain, DRAQ5. 
 
As shown in Figure 2-23 Hela Cells treated with compound 28 (10 µM) under non-
reducing conditions clearly exhibit blue fluorescence between 425 -475 nm while 
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under similar conditions cells treated with compound 45 (10 µM) show intense 
green fluorescence between 525 – 575 nm. 
Upon subjecting Hela cells containing compound 28 (10 µM) to reducing 
conditions a rapid and obvious fluorescence change is observed whereby the blue 
fluorescence is quenched and the green fluorescence between 525 – 575 nm is 
switched on. 
This result suggests the reduction of compound 28 to release compound 45 under 
reductive stress condition in cells was successful. The emission spectra of the 
compounds recorded within cells of figure 2-24 demonstrated that the λmax of 
compound 28 was 465 nm (range 410 to 595 nm), whilst the λmax of compound 45 
was 512 nm (range from 456 to 661 nm). Incubation of compound 28 under 
reducing conditions in HeLa cells revealed a cellular λmax of 512 nm (range 428 to 
659 nm), again suggesting successful reduction of compound 28 under these cell 
culture conditions. 
 
 
Figure 2-24: Emission spectra of treated cells measured using confocal 
microscopy. 
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Figure 2-25: Uptake of compound 29 and 43 (10 µM) by HeLa cells measured 
using confocal laser scanning microscopy (A) cellular localisation of compound 
29 and 43 at 37°C, (B) emission spectra of treated cells measured using confocal 
microscopy. 
 
While same experiment conducted on compound 29, which we injected 29 (10 µM) 
into HeLa cells and observed the fluorescence change. The emission spectra for 
compound 29 and reference compound 43 showed separate λmax value of 446 nm 
and 521 nm respectively (figure 2-25 B). When compound 29 was injected in HeLa 
cells treated with NTR and NADPH as co effector, there was no fluorescence 
change we can receive from the cell, in other words, the blue fluorescence did not 
shift to green. And the emission spectra used to trace the experiment did not 
receive the any signal that compound 29 can emit the signal of λmax value of 521 
nm (range from 472 nm to 630 nm). This supports the results of the enzymatic 
spectroscopic studies described above which showed that treatment of 29 with 
NTR did not release 43. 
 
2.7 Conclusions 
In summary, we have reported the synthesis of two 2-nitroimidazole-1,8-
naphthalimide conjugates 28 and 29. Of these two compounds, compound 28 
showed high sensitivity and selectivity to NTR in cells and through a reduction -
fragmentation mechanism, which showed a fluorescence response clearly visible 
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to the naked eye. However, compound 29, although with similar structural features, 
did not show any reaction to NTR in reductive stress environment. Due to its high 
cytotoxicity, compound 29 does not seem to be suitable for NTR detection 
in hypoxia area in cells. In addition, we have demonstrated the applicability 
of compound 28 to cellular detection of reductive stress using both confocal 
microscopy and flow cytometry where compound 28 allows facile 
discrimination of cells under normal conditions and those under reductive 
stress. Considering that nitroreductase is widely studied in bacteria, as well 
as in yeast, trypanosomes and hypoxic tumors and other systems [55], the 
use of ratiometric probes for NTR such as compound 28 will provide new 
perspectives on the role of reductive stress in various diseases. 
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Chapter 3 : Naphthalimide fluorescent sensors for 
nitroreductase: Varying the nitroaromatic 
3.1 Introduction 
 
According to the previous chapter, we had successfully synthesized the compound 
28 which can react well with the NTR enzyme. We used a number of methods to 
demonstrate that compound 28 was indeed capable of reacting with NTR, such as 
photophysical experiments, mass spectrometry, and fluorescence confocal 
microscopy. Compound 28 not only showed good selectivity to NTR but also the 
sensitivity increased with increasing concentration. It underwent a reduction and 
fragmentation and finally released the fluorophore. In contrast, compound 29 
cannot react with NTR in the same environment. Therefore, considering the 
difference between compound 28 and compound 29 we assumed that the 
fluorescence sensor which can have a reaction with NTR in the case of the 
substitution on 4 position (Figure 3-1). With this assumption, we focused on 
compound 28 and attempted to increase the sensitivity of compound 28 by altering 
the substituents attached to the fluorophore and strived to synthesize more efficient 
hypoxic environment sensors.  
 
Figure 3-1: Substitution on 3 position of naphthalimide (left) and 4 position of 
naphthalimide (right) 
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On this basis, we decided to carry out some modifications to compound 28 in order 
to expect more efficient compounds. We intended changing the nitroaromatic 
triggers of compound 28, taking advantage of other aromatic moieties such as 
nitrofuran, nitrobenzene and nitrothiophene shown in Figure 3-2. These functional 
groups have been shown to be readily oxidized by NTR in hypoxic environments. 
In the research of fluorescence sensors for NTR, nitrofuran, nitrobenzene and 
nitrothiophene are frequently used as NTR recognition groups. Such as in 2013 
[41], Zhao and Co-workers published a fluorescence sensor based on resorufin and 
5-nitrofuran to form the compound 11, which reacted with NTR and finally release 
the fluorophore and shift the fluorescence single from colorless to pink. Same year 
in May, they published another fluorescence sensor based on nitrothiophene and 
resorufin as compound 12 [56]. Similar result showed that nitrothiophene can work 
as NTR recognition group. The last example is a nitrobenzene based fluorescence 
sensor for the detection of NTR. The nitrobenzene was reduced by NTR in the 
presence of NADHP and went through a 1,6-rearrangement and release a highly 
fluorescent dye [57]. With all these examples we are confident that nitrofuran, 
nitrobenzene, and nitrothiophene are fully capable of acting as NTR recognition 
groups.  We expect the new compounds with these nitro substitutes not only to 
accomplish their work by reacting with NTR to alter the fluorescence signal but 
also have a higher activity. 
 
Figure 3-2:  Target compounds for sensitivity improvement. 
 
The overall aim of work presented in this chapter is to discuss the development 
and the improvement of compound 28. Firstly, we will discuss the improvement 
of sensitivity for compound 28, and some synthesis procedure will be mentioned. 
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Following by a comparison of the photophysical properties of the resulting 
compound and its response to the enzyme NTR. Then we will discuss the 
improvement of the biological conjugation of the compound 28. As usual, we will 
mention the synthesis procedure of these derivatives. Finally, the reaction of the 
resulting compound to NTR will be mentioned. 
 
 
3.2 Synthesis 
 
 
Scheme 3-1: The synthesis of compound 31 
 
The synthesis of compound 31 showed in Scheme 3-1 was similar as the one with 
compound 28, the only different was that we switched 4-nitrobenzene alcohol 
instead of compound 36. The synthetic procedure had been mentioned in the 
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previous chapter, and the detailed synthesis process was outlined in Chapter 6, so 
it was not described here. 
Compound 31 was characterised by 1H NMR, melting point analysis, mass 
spectrometry, 13C NMR and IR spectroscopy. The 1H NMR spectrum is shown in 
Figure 3-3. Assignment of the peaks was achieved by H-H COSY and C-H COSY 
analysis.  
 
 
Figure 3-3: The 1H NMR spectrum of compound 31 (500 MHz, DMSO-d6) 
 
In the 1H NMR spectrum of compound 31 (Figure 3-3), we can clearly see 13 peaks 
which represent 13 different kinds of H in compound 31. In general, peaks between 
7 ppm to 9 ppm stand for the aromatic H while peaks between 0 ppm to 5 ppm 
indicated the aliphatic H. compound 31 has 7 different aromatic H and 5 different 
aliphatic H which was perfectly match the 1H NMR spectrum. 
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Figure 3-4: The comparation of compound 28 and compound 31 
 
 If we compared this spectrum of compound 31 with the spectrum of compound 
28 in Figure 3-4 we can see the chemical shift of butyl group of compound 31 was 
same as the chemical shift of compound 28. Even the chemical shifts of the CH2 
groups on the side of the two carbamates of the compounds were very similar. In 
the aromatic region, we can clearly see 5 different H signals integrated 1 which 
represent the H on the naphthalimide and two signals integrated to 2 which 
indicated the Hs on the nitrobenzene because the hydrogen on the benzene ring is 
symmetrical. Peak at 10.5 ppm integrated 1 indicated the hydrogen of NH because 
we did not see signal at this chemical shift in HSQC, which means there was no 
hydrogen connect to carbon and since there was a signal on 1H NMR spectrum we 
can ensure that the chemical shift at 10.5 ppm was NH peak. Peak at 5.76 ppm was 
the solvent peak of DCM and signal at 3.17 ppm was the methanol peak. At this 
point, all of the signals corresponded to compound 31 and we did have reason to 
believe compound 31 had not been made successfully. 
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Scheme 3-2: The synthesis of compound 32 
 
For the synthesis of compound 32 in Scheme 3-2, we used the same procedure as 
compound 28 but different starting material. In the synthesis of compound 32, 
compound 46 was reduced from its aldehyde form 5-nitro-2-
thiophenecarboxaldehyde using sodium borohydride. The 1H NMR spectrum is 
shown below. With those starting materials in hand, compound 32 was synthesised 
as previously described. 
 
 
Figure 3-5: The 1H NMR spectrum of compound 46 (500 MHz, CDCl3) 
 
From the spectrum shown in Figure 3-5, we can see there are three relevant peaks 
which indicated three different hydrogens of compound 46. Peak at 4.85 ppm 
integrated to 2 represents H1 and peak at 7.93 ppm stands for H3 as it was more 
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close to electron withdrawing group which make the H more de-shielded. Peak at 
6.91 ppm stands for the H2.  
Compound 32 was characterised by 1H NMR, melting point analysis, mass 
spectrometry, 13C NMR and IR spectroscopy. The 1H NMR spectrum was shown 
in Figure 3-6. Assignment of the peaks was achieved by H-H COSY and C-H 
COSY analysis.  
 
 
Figure 3-6: The 1H NMR spectrum of 32 (500 MHz, DMSO-d6) 
 
 
From the 1H NMR spectrum in Figure 3-6, peaks between 7 ppm to 9 ppm were 
signals of aromatic H on naphthalimide and thiofuran groups. While peak at 5.44 
ppm was a singlet and integrated to 2 which represented the signal of H11. H1, H2, 
H3 and H4 represented the butyl group of compound 32. The peak with chemical 
shift at 10.5 ppm was very similar as compound 31, which was proved to be the 
single NH. In this situation, each peak stand for one single of compound 32, 
therefore, we can ensure that compound 32 has been made successfully. 
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Scheme 3-3: The idea path for the synthesis of compound 30 
 
The synthesis of compound 30 was just the same as compound 32 in Scheme 3-3, 
while the synthesis of the nitroaromatic trigger was successful by reducing the 5-
nitrofuran-2-carbaldehyde to (5-nitrofuran-2-yl) methanol 47 with sodium 
borohydride in MeOH. The 1H NMR is shown below in Figure 3-7. 
 
Figure 3-7: The 1H NMR spectrum of 47 (500 MHz, CDCl3) 
 
The 1H NMR spectrum was shown in Figure 3-7, compound 47 was very similar 
to compound 46 as it had three signals. Peak at 4.69 ppm integrated to 2 stands for 
H1 and peak at 7.26 ppm integrated 1 stands for H3 as it was more close to nitro 
group. Peak at 6.53 ppm stands for H2 and peak at 5.28 ppm was solvent DCM. 
When we tried to combine the fluorophore with (5-nitrofuran-2-yl) methanol 
compound 47 through a carbamate linker. The compound 30 exhibited its high 
degree of instability and converted to its starting material again according to the 
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1H NMR spectrum in Figure 3-8, there was no single at 10.5 ppm which means 
there was no NH peak formed and the Mass spec did not find the peak for 
compound 30. Changed the experimental procedure by reacting the compound 47 
with phosgene first and then the fluorophore was added. The result showed that it 
was still not working for compound 30. Taken into account its instability, 
compound 30 would not be used as fluorescence sensor for NTR. 
 
Figure 3-8: The 1H NMR spectrum of the crude product after the reaction of 
Scheme 3-3 (500 MHz, CDCl3) 
 
 
Since compound 30 could not be made, our next wish was to compare compound 
31 and 32 with compound 28 and 29 to find out the most sensitive probe to NTR. 
 
3.3 Preliminary test for NTR 
 
In this section, we investigated the spectral properties of 31 and 32 when placed 
under reductive stress conditions by treatment with NTR in the presence of NADH. 
And by comparing with the emission spectrums of those compounds, we wish to 
find out the most sensitive probe for NTR. 
The emission spectrums were measured in PBS (pH 7.4, 10 Mm) with 0.5% 
DMSO as co-solvent in the presence of NADPH (50 µM, as a cofactor of NTR) at 
25 °C. 
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We treated compound 32 with 0.5 µg NTR in the PBS and recorded the 
fluorescence change every 2 mins, herein we can see an emission spectrum (Figure 
3-9) with intensity change over time. The emission maximum at 475 nm was 
slightly decreased during the time while the emission at 550 nm was increased. 
The experiment showed that compound 32 does react with NTR to some extent, 
but the intensity change was very small to observe. The fluorescence change of 
compound 32 was also very small, which was not easily visible to the naked eye. 
 
Figure 3-9: Changes in the emission spectrum of 32 (10 µM) at various time points 
(0 - 25 mins) after addition of NTR (1 µg mL-1). 
 
The same experiment was conducted with compound 31, and we treated compound 
31 (10 µM) with NTR (1 µg mL-1) in the presence of NADH. The fluorescence 
intensity change was shown below in Figure 3-10. The emission maximum at 476 
nm was seen to decrease while the emission at 550 nm was again increased. The 
emission intensity change at 476 nm showed that compound 31 does react with 
NTR but the magnitude of the change was very small. From the spectrum we knew 
that the intensity at 476 nm had a 3-fold decrease and there was also a 2-fold 
increase of intensity at 550 nm, which means that compound 31 was transferred to 
its fluorophore under the reaction of NTR. 
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Figure 3-10: Changes in the emission spectrum of 31 (10 µM) at various time 
points (0 - 25 mins) after addition of NTR (1 µg mL-1). 
 
After having all the emission intensity change experiments, we compared all the 
emission spectrums together and assessed their sensitivity to NTR. Compound 28 
and 29 was the first generation compounds and compound 32 and 31 was modified 
based on compound 28. 
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Figure 3-11: Changes in the emission spectrum of 28, 29, 32 and 31 (10 µM) at 
various time points after addition NTR. 
 
In the comparison of Figure 3-11, we can clearly see those 4 compounds with their 
fluorescence change over time. Compound 29 has very little change at 460 nm and 
still very little change at 590 nm and after the MS experiment, we can indicate that 
compound 29 was not suitable as a substrate for NTR. The spectrum of compound 
32 did not show any intensity change at 475 nm but there was a 30% increase in 
intensity at 550 nm. The situation of 31 was better than compound 32 while it had 
a 3-fold decrease signal at 476 nm and 2-fold intensity increase at 550 nm. Since 
compound 32 showed more or fewer changes in the response to NTR, compounds 
32 were believed to be able to react with NTR to alter the fluorescence, but due to 
their relatively low sensitivity to NTR, a particularly high concentration of those 
compounds were required to show a significant fluorescence change. Compound 
31 had a great response when reacted with NTR compared with compound 32 and 
29. However, the value of the intensity was quite low compared to the value of 
compound 28, therefore, we believe compound 31 would have an affection with 
NTR only in a very high concentration environment. Among them, compound 28 
showed the highest sensitivity to NTR as there was a 5 fold decrease of signal at 
475 nm and an 8 fold increase of signal at 550 nm than before which gave a very 
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clear fluorescence change from blue to green. More importantly, in the reaction of 
compound 28 with NTR, the concentration of NTR was 0.5 µg mL-1, which was 
lower than the reaction concentration of the other various test compounds (1 µg 
mL-1), meaning that compound 28 requires only a smaller concentration to give 
higher reaction intensity. 
 
Figure 3-12: Relative Intensity change at 550 nm overtime for these 4 compounds 
 
In order to make the comparison more clear, we took the intensity at 550 nm for 
all 4 compounds at different time and compared the trend of the intensity which 
showed in Figure 3-12. As we can see, compound 29 was almost a parallel line 
which means the intensity at 550 nm had nearly no change. The change of 
compound 32 was also very small while compound 31 had a relative higher change 
than compound 31 and compound 29. Finally compound 28 showed the most 
sensitive change among these 4 compounds. This result also matched the 
observation above which compound 28 had the best activity with NTR. 
 
3.4 Conclusion 
 
Of all the tested compounds, compound 28 showed the highest chemical activity 
and reached the highest sensitivity with minimal concentration. We were 
convinced of the advantages of nitroimidazole as an NTR identification group and 
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compound 28 was studied as a major NTR probe. On the other hand, compound 
31 showed the second best activity to NTR compared with compound 29 and 
compound 32, the emission spectrum of compound 31 had great change when 
treated with NTR and compound 31 had transferred to its fluorophore during the 
change. However, if we compared the emission spectrum of compound 31 with 
the emission spectrum of compound 28 we can see a huge difference between the 
intensity values of each spectrum. Compound 45 had a 5-fold decrease of the 
signal at 475 nm while compound 31 had only 3-fold decrease of single at 476 nm, 
similarly, there was an 8-fold increase of signal at 550 nm for compound 28 when 
reacted with NTR compared with a 2-fold increase of single at 550 nm of 
compound 31. This result showed that compound 28 had higher sensitivity for 
NTR than compound 31. 
Since compound 31 and 32 did not show very high sensitivity to NTR, we decided 
not to proceed with further study of them. Compound 28 still showed the strongest 
activity and was our main research focus. Next, we intended to make some 
structural modifications to compound 28, without affecting its ability to recognise 
NTR while simultaneously enabling its conjugation to molecules of interest. 
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Chapter 4 : Naphthalimide fluorescent sensors for 
nitroreductase: A toolkit for bioconjugation 
4.1 Introduction 
 
In the former chapters, we knew that compound 28 had the highest sensitivity to 
NTR mediated reduction. The difference between compound 28 and other 
compounds under study was thought to be depended on the substitution pattern of 
the naphthalimide (substitution at the 4 position was found to be optimal) and the 
nitroaromatic trigger (2-nitroimidazole was found to be optimal). In this case, we 
turned our focus on the N-terminus of the compound 28. We intended to modify 
the structure of compound 28 to enable bioconjugation of the NTR to important 
biomolecules or to attain selective uptake in subcellular organelles. The N-terminal 
consisting of n-butyl group could be changed to other substituents to enhance the 
ability of compound 28 to either undergo bioconjugation or to allow specific 
uptake (Figure 4-1). Tumor cells have a series of biological features, such as 
unlimited potential for replication, anti-growth inhibitory signal, anti-apoptotic, 
continued to produce proliferative signals, induce angiogenesis and invasion and 
metastasis, etc. [4]. Since mitochondria can regulate apoptosis of cells, most of 
mitochondria of tumor cells show abnormalities, such as poor permeability of the 
outer membrane, cannot be timely release of apoptotic signals, mitochondria also 
become the target of cancer treatment [58]. Mitochondria play an important role 
in cells: on the one hand, mitochondria are cells' energy factories that decompose 
carbohydrates to produce ATP, which provides most of the energy required for 
metabolism and movement of living organisms [59]; on the other hand, 
mitochondria participate in the process of apoptosis [60]. The drug targeting of 
mitochondria mainly includes lipophilic cations and mitochondrial protein import 
[61]. The main mitochondrial targeting ligands are triphenylphosphine (TPP) and 
its derivatives such as octadecyl triphenylphosphine (STPP), as well as gold ions 
and nitrogen heterocyclic complexes (NHCs), KLA polypeptide ( KLAKLAK), 
αvβ3 family of polypeptides [62] [63]. Mitochondrial is important in hypoxic 
cancer research, as most of the reduced products form and accumulate in 
mitochondria [64]. If the compound can easily enter the mitochondria, then the 
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compound can more effectively react with the reducing substance such as 
nitroreductase. In order to further enhance the ability of compound 28 to target the 
mitochondrial, we envisioned the introduction of mitochondrial targeting of 
triphenylphosphine to make the probe more accurately reach its target. 
In this section, we will discuss the synthesis of modified compounds based on 
compound 28 and the characterisation of those compounds to identify that all 
compounds needed were made successfully. 
 
 
 
Figure 4-1: Target compounds for bioconjugation based on compound 28 
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4.2 Synthesis  
 
 
 
Scheme 4-1: The synthesis of compound 48 
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The synthesis of compound 48 shown in Scheme 4-1 was achieved using an 
intermediate in the synthetic pathway of 2-nitro-imidazole. The synthesis of 
compound 51 was achieved using ethyl diamine mono-protected using di-tert-
butyl dicarbonate in chloroform to yield a colourless liquid in 90 % yield. 
Compound 51 was characterised by 1H NMR, melting point analysis, mass 
spectrometry, 13C NMR and IR spectroscopy. Assignment of the peaks was 
achieved by H-H COSY and C-H COSY analysis.  
 
Figure 4-2: The 1H NMR spectrum of compound 51 (500 MHz, DMSO-d6)  
 
From the spectrum in Figure 4-2, we can see 5 signals which represent 5 different 
H of compound 51. Peak at 1.44 integrated 9 represents three CH3 groups because 
they were in the same chemical environment. And peaks at 2.79 ppm and 3.15 ppm 
stand for 2 aliphatic H and since they all integrated 2, therefore, they represent the 
two CH2 groups of compound 51. Peak at 7.42 ppm stands for NH in the middle 
because it was more close to ester group which is an electron withdrawing group, 
so it will shift the NH to down field and finally, peak at 5.49 ppm stands for the 
other NH group. 
 
The remaining scheme followed the same strategy as compound 28, reacting with 
4-nitro-1,8-naphthalic anhydride and reducing the nitro group with H2 and Pd/C to 
form the fluorophore of compound 53. Finally, compound 53 was reacting with 
compound 36 as previously described to form the final product compound 48. 
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Compound 48 was characterised by 1H NMR, melting point analysis, mass 
spectrometry, 13C NMR and IR spectroscopy. Assignment of the peaks was 
achieved by H-H COSY and C-H COSY analysis. Successful formation of this 
trigger was also evident from accurate mass spectrometry. 
 
 
 
Figure 4-3: The 1H NMR spectrum of compound 48 (500 MHz, DMSO-d6) 
 
As seen in Figure 4-3, there were some similar peaks compared with compound 
51. H1 stands for the signal at 1.22 ppm which integrated 9 and peaks at 3.24 ppm 
and 4.13 ppm stand for the 2 CH2 groups of the diamine at the top compared with 
compound 51. And the singlet peak at 7.37 ppm integrated 1 stands for H2. The 
rest peaks were similar as compound 28 while there were 6 aromatic peaks which 
match the H of compound 48 and peak at 10.4 stands for the other NH10 of 
compound 48. Finally, the singlet peak at 5.4 ppm integrated to 2 stands for H11. 
From the two spectra were confident that compound 48 had been made 
successfully. 
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Scheme 4-2: The synthesis of compound 49 
 
The synthesis of compound 49 in Scheme 4-2 also took us great efforts. The first 
step was introducing mitochondrial targeting of triphenylphosphine on the top of 
naphthalimide. We had tried 1-bromoethylamine to be the linker to connect the 
triphenylphosphine with 4-nitro-1,8-naphthalic anhydride (Scheme 4-3). With the 
1-bromoethylamine as linker the reaction was unsuccessful, however, with the 1-
bromopropylamine as linker the reaction was successful, the reason we thought 
was that the number of the carbon on the chain is too little and cannot afford two 
big molecules. The steric hindrance between macromolecules is also a reason that 
this compound is not working. 
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Scheme 4-3: Problems encountered in the experiment 
 
Therefore, we chose 1-bromopropylamine to connect the triphenylphosphine. 1-
bromopropylamine and triphenylphosphine were refluxed in CH3CN for 24 hr. 
Cooled the solution to room temperature and heated the solution again to reflux to 
yield precipitate. Removed the solvent when it was cooled down and the solid was 
washed with DCM to yield a white compound 54 with 46.4 % yield.  
With compound in hand, 4-nitro-1,8-naphthalic anhydride and compound 54 were 
reacted and after the reduction it formed compound 56. Compound 56 was reacted 
with compound 36 in the presence of phosgene to make the final product 
compound 49. 
 
Figure 4-4: The 1H NMR spectrum of compound 55 (500 MHz, DMSO-d6) 
 
Compound 49 was characterised by 1H NMR, melting point analysis, mass 
spectrometry, 13C NMR and IR spectroscopy. The 1H NMR spectrum was shown 
 90 
 
in figure below. Assignment of the peaks was achieved by H-H COSY and C-H 
COSY analysis. Successful formation of this trigger was also evident from 
accurate mass spectrometry. 
We took compound 55 as an example, from the spectrum in Figure 4-4 we can see 
there were two signals which integrated 3 and 12 indicated the hydrogens of 
triphenylphosphine and there were also 5 signals at range 8 ppm to 9 ppm indicated 
those five aromatic hydrogens of the naphthalimide. There were also three signals 
at 4.25 ppm, 3.76 ppm and 2.01 ppm integrated 2 stand for those three CH2 group 
of compound 55. While peak at 5.76 ppm was the DCM solvent peak. 
 
Figure 4-5: The comparison of compound 56 and compound 49 
 
The Figure 4-5 was the comparison of compound 56 and 49. From the figure we 
can see that there were few new signals show up of compound 49. The peak at 
10.3 ppm was singlet and integrated 1, from the HSQC in Figure 4-6 we did not 
see any single at this chemical shift, so we can certainty the single was the NH of 
compound 49. And there were two aliphatic signals showed up at 6.7 ppm and 4.3 
ppm which should be the CH2 group and CH3 group of the nitroimidazole group. 
Consider to this, we can make sure that compound 49 was made successfully. With 
the comparison of compound 56, we can indicate the signals of this spectrum to 
each hydrogen of compound 49. 
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Figure 4-6: The HSQC of compound 49 (500 MHz, DMSO-d6) 
 
 
Figure 4-7: 1H NMR spectrum of compound 49 (500 MHz, DMSO-d6). 
 
In Figure 4-7, peak at 7.9 ppm stands for H1 and peak at 7.76 ppm integrated 12 
stand for H2 and H3. The peaks chemical shift at the range of 8 to 9 stand for the 
aromatic hydrogens H7, H8, H9, H10, H11 and H14 respectively. There is a big 
single at 5.6 ppm and some little singles around 5.6 ppm which indicate the peak 
of DCM and the satellite peaks of DCM. Peaks at 1.99 ppm, 3.72 ppm and 4.2 ppm 
stand for the propyl group of the compound 49 and peak at 6.7 ppm stand for H13 
while peak at 4.3 ppm was H15. Finally, chemical shift at 10.3 ppm was the NH 
of compound 49. 
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Scheme 4-4: The synthesis of compound 50 
 
The synthesis of compound 50 shown in Scheme 4-4 was the same as compound 
28. However, due to the presence of carboxyl groups, compound 50 cannot be 
purified by passing through the column. So we used HPLC purification to make 
sure we got high purity compounds. The purification was performed using a 
mobile phase of 0.1% formic acid in water as solvent A and 0.1% formic acid in 
acetonitrile solvent B and a linear gradient of 0-100% B over 30 min. 
Compound 50 was characterised by 1H NMR, melting point analysis, mass 
spectrometry, 13C NMR and IR spectroscopy. The 1H NMR spectrum is shown in 
figure below. Assignment of the peaks was achieved by H-H COSY and C-H 
COSY analysis. 
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Figure 4-8: The 1H NMR spectrum of compound 58 (500 MHz, DMSO-d6). 
 
We took compound 58 as reference. From the spectrum in Figure 4-8 we can see 
there were 5 aromatic signals which indicated those 5 aromatic hydrogens of 
compound 58 and there was a singlet which integrated 2 stand for the NH2 group 
and there were 5 aliphatic signals which clearly stand for 5 CH2 groups of 
compound 58. This picture clearly showed the signal of each hydrogen of 
Compound 58. Now we compared the spectrum of compound 58 with the spectrum 
of compound 50 we made to see if we can certainty our final compound was 
perfectly made. 
 
 
Figure 4-9: The comparison of compound 50 and compound 58 
 94 
 
 
From the comparison in Figure 4-9 we knew that the aromatic hydrogens of 
compound 50 were moved to down field because the conjugation of carbamate 
linker lower the electron density of the naphthalimide group which cause de-shield 
and pushed the signal to down field. There were another aliphatic signals showed 
up from the spectrum of compound 50 which indicated the CH2 and CH3 groups 
of the nitroimidazole group. Finally there was an aliphatic signal at 2.2 ppm which 
was covered by the solvent acetone. 
 
 
Figure 4-10: The 1H NMR spectrum of compound 50 (500 MHz, DMSO-d6). 
 
Therefore, we can indicate the signals of compound 50. In Figure 4-10, peak at 
1.36 ppm, 1.54 ppm, 1.65 ppm and 4.03 ppm stand for H1, H2, H3 and H5. While 
there was still a signal at 4.03 ppm stand for H13. Peak at 5.41 integrated 2 stand 
for H11 and the singlet at 7.37 ppm indicated H12. The peak at 8.68 ppm stand for 
the H9 because it was more close to the carbamate linker and the triplet signal at 
7.86 ppm was the H7. The NH peak was showed up at 10.5 ppm but it was 
overlapped by the base line. Hence we measured the Mass Spec to test our 
compound which shown in Figure 4-11. 
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Figure 4-11: Mass Spec of compound 50 
 
The first part of Figure 4-11 was the absorption of the compound 50. And the 
second part was the ions detected at this absorption peak with the molecular weight 
of 510 (the molecular weight of compound 50 is 509), and the final part was the 
Mass spectrum of compound 50. Here we can clearly see the signal that the 
compound 50 is ionized by hydrogen ions and sodium ions. Therefore, we may 
certainty say that compound 50 was made successfully. 
 
4.3 Conclusion 
 
After a series of modifications to compound 28, compounds 48, 49 and 50 were 
successfully synthesized. The key to the successful synthesis of these compounds 
is the selection of the correct synthesis procedure and the appropriate separation 
technique. For example, when triphenylphosphine was linked to naphthalene 
anhydride to form compound 55, the length of the carbon chain was not enough 
would causes the two macromolecules to be too close together to form a steric 
hindrance and finally prevent the formation of compound. In the purification of 
compound 50, the silica gel column adsorbs the compound on the column without 
obtaining the product, but if we used HPLC purification the pure product will show 
up easily. Overcoming the problems and difficulties encountered in synthetic 
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chemistry is the foundation of our progress, and the experience in these research 
processes has a profound influence for our future development. 
These compounds are able to bind to biological macromolecules in vivo, providing 
a great help to compounds in targeting cells. We believe that changing the structure 
of the N-terminal of the compound will not affect the compounds’ own sensitivity 
to NTR. Although NTR reactions have not been conducted to demonstrate the 
properties of these compounds, we are still fully confident in those compounds and 
we believe compounds 48, 49, 50 can all be used as NTR fluorescent sensors. 
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Chapter 5 Conclusion and Future work 
Conclusion 
 
In summary, during our research, we successfully synthesized compounds 28 and 
29, and we studied their photophysical properties, in addition, we also conducted 
a deep discussion on their fluorescence properties with NTR treated. The reason 
for the study of compounds 28 and 29 was to explore the important properties of 
the fluorescent sensors by comparing the similarities and differences between the 
two compounds. We kept the fluorophore and the nitro imidazole same but change 
the binding position to see if these two compounds have response to NTR (Figure 
5-1). 
 
Figure 5-1: The difference between compound 28 and compound 28 
 
On the other hand, in the experiment of enhancing the sensitivity of compound 28, 
we further synthesized fluorescent probes based on different nitroaromatic triggers 
such as nitrobenzene and nitro thiofuran to form compounds 31 and 32 (Figure 
5-2). We would like to find out which nitro aromatic trigger has the best response 
to NTR. The NTR reactions with them were also investigated.  
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Figure 5-2: The change on the nitro aromatic triggers 
 
Finally, we performed a bioconjugation experiment on compound 28 to improve 
the ability of compound 28 to bind to a given functional group (Figure 5-3). For 
this reason, we have successfully synthesized compounds 48, 49 and 50 to adapt 
to the combination of various functional groups. 
 
Figure 5-3: Bioconjugation of compound 28 
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In these experiments, we fully understand some of the important properties of the 
probe based on naphthalene anhydride as a fluorescent group: the compound made 
through 4-position substituted of naphthalimide has a more pronounced NTR 
response than the compound substituted at the 3-position. In the first set of 
experiments, compound 28 exhibited a very high sensitivity to NTR reactions. It 
was clearly shown by fluorescence emission spectroscopy that the compound 28 
reacted rapidly under the action of NTR, eventually releasing the fluorophore 
through a bond breaking and rearrangement reaction and finally change the 
fluorescence signal. On the other hand, compound 29 did not show any change in 
fluorescence intensity under the action of NTR. We therefore determined that the 
substitution of naphthalene 4 position is the key to the reaction with NTR. 
Through biological experiments, we know that compound 28 was transported into 
cells by passive transport, which means that compound 28 can enter cells without 
any energy retention. 
In addition, during the NTR sensitivity experiment, we tested all the compounds 
we made from different nitroaromatic triggers with NTR and recorded their 
fluorescence intensity. We found that compound 28 had the best change during 
reacting with NTR while there was no particularly strong fluorescence change of 
the fluorescent probes synthesized by other aromatic nitro substituents at the same 
concentration. Therefore, we concluded that nitroimidazole as an NTR recognition 
factor has the advantage that other aromatic nitro compounds cannot be replaced. 
These experiments confirmed the advantage of compound 28 in the detection of 
hypoxic tumors. Similarly, the novel compounds 48, 49 and 50 synthesized on the 
basis of compound 28 are also highly promising as tumor fluorescent probes to 
play an important role in this field. 
 
Future work 
 
The successful NTR reaction of compound 28 with HeLa cells demonstrated that 
the potential value of compound 28 as a hypoxia fluorescent probe. Our next phase 
of research will focus on the detection of hypoxia in living tissues. Although the 
optical imaging technology has its own unique advantages, it has not been widely 
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used in clinical practice. An important reason is the lack of suitable for in vivo 
tissue hypoxia probe. During the hypoxia probe research, people mainly using 
adherent cells to react with the probes. While there is a huge difference between 
adherent cells and three-dimensional living tissue. Probes which show great 
affection in adherent cells might not have the same result in living tissue due to 
the tissue permeability and other issues that it cannot penetrate the tumor hypoxia 
centre. Therefore, increasing the solubility of compounds is an important way to 
solve the problem. When it comes to increasing the solubility of the compounds, 
we envisaged that the polarity of the compounds could be increased by the 
introduction of polar functional groups. Another way to increase the solubility is 
to form coordination complex or salt of the compound by the reaction of 
hydrotropic agent. 
In the meantime, we would like to change the structure of compound 28 by 
exchanging the nitroaromatic trigger to the N terminal to form a set of novel 
fluorescence compounds (Figure 5-4). 
 
Figure 5-4: Novel fluorescence sensors in the future 
 
Also, we could modify the nitro aromatic triggers to not only act as the NTR 
recognition group but also can carry some drug molecules into the cells (Figure 
5-5). In this case, the nitro aromatic triggers can connect to some drug molecules 
and once the compound reacts with NTR in cells it will bring the drug molecule 
into the cells as well. 
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Figure 5-5: Novel fluorescence sensors by modifying the nitroaromatic triggers 
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Chapter 6 Experiments  
6.1 General remarks 
 
1H NMR spectra were recorded using a Bruker Avance III 500 at a frequency of 
500.13 MHz, and are reported as parts per million (ppm) with either DMSO-d6 (δH 
2.50 ppm) or CDCl3 (δH 7.26 ppm) as an internal reference. The data are reported 
as chemical shift (δ), multiplicity (br = broad, s = singlet, d = doublet, t = triplet, 
m = multiplet), coupling constant (J Hz) and relative integral. 13C NMR spectra 
were recorded using a Bruker Avance III 500 at a frequency of 125.76 MHz and 
are reported as parts per million (ppm) with either DMSO-d6 (δH 39.5 ppm) or 
CDCl3 (δH 77.2 ppm) as an internal reference. High resolution ESI spectra were 
recorded on an Agilent 6310 LCMS TOF. Analytical TLC was performed using 
pre-coated silica gel plates (Merck Kieselgel 60 F254). Microwave irradiation of 
reaction mixtures was performed using a CEM Discover SP microwave controlled 
by SynergyTM software.  
6.2 Materials and Methods for Biological Experiments: 
6.2.1 Nitroreductase Studies 
 
Fluorescence titrations were carried out using a Cary Eclipse Fluorescence 
Spectrometer or a Jasco FP6300 spectrofluorimeter. A stock solution of the 
fluorescent probe under study was prepared in DMSO before being diluted in a 3 
mL quartz fluorescence cell to a final concentration of 1 × 10-5 M with NADH (50 
µM) in 10 mM phosphate buffer solution (PBS) where the total amount of DMSO 
present was < 0.1%. Spectroscopic titrations were performed by additions of 
aliquots of a 1 µg/µL Nitroreductase (from Escherichia coli, ≥90% (SDS-PAGE), 
recombinant, expressed in E. coli), followed by either continuous scanning of a 
single wavelength or by intermittent fluorescence spectra recorded from 400 nm 
to 750 nm. Typically, 0 up to 24 µg/mL of NTR was added to the solution. ESI-
LCMS studies were conducted on an Agilent 6310 LCMS TOF with samples 
prepared to a final concentration of 1 × 10-3 M with NADH (50 µM) in 10 mM 
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phosphate buffer solution (PBS) where the total amount of DMSO present was < 
0.1%.  
6.2.2 Cell culture  
 
HeLa cells were grown in Dulbecco’s Modified Eagle Medium supplemented with 
10% fetal bovine serum and 50 µg/ml penicillin/streptomycin at 37˚C in a 
humidified atmosphere of 5% CO2. For reducing conditions, compounds were pre-
treated for 3 hrs with nitroreductase and its cofactor NADH before being added to 
cells. For endocytosis studies, cells were pre-treated for 3hrs with 100 µM 
dynasore. 
6.2.3 Viability assay  
 
5x103 cells/well were seeded in a 96-well plate and treated with the respective 
compound for 24 h. Alamar Blue (20 µl) (BioSource) was then added to each well 
and incubated for 4 h. Fluorescence was read using at 590 nm (excitation 544 nm). 
The control untreated cells represented 100% cell viability. All data points 
(expressed as means ± S.E.M.) were analysed using GRAPHPAD Prism (version 
4) software (Graphpad software Inc., San Diego, CA). 
6.2.4 Confocal microscopy 
 
HeLa cells were seeded at a density of 1 x 105 cells /2 mL and left for 24 h before 
the required treatment. Cells were then washed twice, stained with the red nuclear 
stain DRAQ5 and analysed by live confocal microscopy using an Olympus 
FV1000 point scanning microscope with a 60x oil immersion lens with an NA 
(numerical aperture) of 1.42.  The software used to collect images was FluoView 
Version 7.1 software. Compounds were excited by a 405 nm argon laser, emission 
425-475 and 525-575 nm. DRAQ5 was excited by a 633 nm laser, emission >650 
nm. For spectra, emission from 410 to 770 nm was quantified using a Leica SP8 
confocal microscope (60X oil immersion lens), excitation 405 nm. 
6.2.5 Flow cytometry 
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Following the required treatment, cells were trypsinised, washed twice with PBS, 
resuspended in 400 µL of ice cold PBS and assayed for flow cytometry (FACS 
CyAn, Bectin Dickson). Analysis was performed using appropriate gates, counting 
10,000 cells and the FlowJo software package. The compounds were excited by a 
405 nm laser, emission filters 425 nm-475nm and 510 nm-550nm. 
 
6.3 Experimental procedure 
 
3-nitro-N-butyl-1,8-naphthalimide (42) 
 
                                                  
3-nitro-1,8-naphthalic anhydride (1 g, 4.1 mmol, 1 eq.) and butyl amine (0.31 g, 
0.406 ml, 4.1 mmol, 1 eq.) were dissolved in EtOH (17 mL) before being heated 
at 110 oC for 1 hr under microwave irradiation. The mixture was allowed to cool 
to room temperature before the solvent was removed under reduced pressure. The 
resulting residue was purified by column chromatography eluting with DCM. The 
purified product was isolated as a cream solid (1.2 g, 97% yield). 1H NMR (500 
MHz, DMSO-d6) σ 9.41 (d, 1H, J = 2.3 Hz), 8.89 (d, 1H, J = 2.3Hz), 8.72 (dd, 1H, 
J = 8.4/0.82 Hz), 8.62 (dd, 1H, J = 7.4/1.2 Hz), 8.01 (dt, 1H, J = 7.4/0.75 Hz), 4.03 
(t, 2H, J = 7.49 Hz), 1.62 (qu, 2H, J = 7.48 Hz), 1.36 (sex, 2H, J = 7.47 Hz), 0.93 
(t, 3H, J = 7.47 Hz); 13C NMR (125 MHz, DMSO-d6): 163.24, 162.73, 146.29, 
136.74, 134.38, 131.31, 130.12, 129.97, 129.71, 124.48, 123.32, 123.04, 29.99, 
20.25, 14.19; HRMS (ESI): Calculated for C16H15N2O4 [M+H]
+, expected: 
299.1035, observed: 299.1026, PPM: 3.03; max (film)/cm-1: 3089.47, 2965.46, 
2937.14, 2876.14, 1993.10, 1837.2, 1707.12, 1598.98, 1547.54, 1508.57, 1462.63, 
1437.21, 1418.73, 1352.05, 1327.24, 1267.73, 1241.87, 1203.19. MP: 130~136 
oC. 
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3-amino-N-butyl-1,8-naphthalimide (43)  
 
                                                         
3-nitro-N-butyl-1,8-naphthalimide (1.2g, 4 mmol, 1 eq.) was dissolved in MeOH 
(70 ml) before Pd/C (0.25 g) was added and the reaction was placed under an 
atmosphere of H2. The reaction was allowed to proceed for 2 hrs before being 
filtered through a pad of celite. The solvent was removed under reduced pressure 
to yield a bright yellow solid. (1.05 g, 98% yield) 1H NMR (500 MHz, DMSO-d6) 
σ 8.13 (dd, 1H, J = 7.12/1.13Hz), 8.08 (dd, 1H, J = 8.4/1.0Hz), 8.02 (d, 1H, J = 
2.32Hz), 7.67 (dt, 1H, J = 7.3/1.03Hz), 7.34 (d, 1H, J = 2.32Hz), 6.04 (s, 1H), 4.08 
(t, 2H, J = 7.4Hz), 1.65 (qu, 2H, J = 7.32Hz), 1.41 (sex, 2H, J = 7.48Hz), 0.98 (t, 
3H, J = 7.48Hz). 13C NMR (125 MHz, DMSO-d6): 164.24, 164.05, 148.34, 134.02, 
131.92, 127.42, 125.88, 123.04, 122.24, 122.18, 121.04, 112.18, 79.42, 30.17, 
20.27, 14.19; HRMS (ESI): Calculated for C16H17N2O2 [M+H]
+ , expected: 
269.1298, observed: 269.1285, PPM: 4.86; max (film)/cm-1: 3467.96, 3364.16, 
3065.44, 2959.11, 2863.58, 1691.26, 1652.47, 1629.40, 1580.68, 1516.78, 
1449.69, 1388.59, 1341.53, 1306.06, 1218.14. MP: 150~162 oC. 
 
 
(2-Butyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)-carbamic acid 
3-methyl-2-nitro-3H-imidazol-4-ylmethyl ester (29)  
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3-amino-N-butyl-1,8-naphthalimide (48 mg, 0.18 mmol, 1 eq.) and DMAP (66 mg, 
0.54 mmol, 3 eq.) were dissolved in anhydrous DCM (20 mL) and placed under 
an argon atmosphere. The reaction was cooled to -10°C using an ice and salt bath 
before phosgene solution (15 wt. % in toluene; 0.7 ml, 1.07 mmol, 6 eq.) was added 
dropwise and the reaction mixture was allowed warm to room temperature and 
stirred for 4 hrs. The reaction mixture was reduced to dryness by bubbling with 
argon before the residue was redissolved in anhydrous DCM and cooled to 0 °C 
(20 mL). (3-Methyl-2-nitro-3H-imidazol-4-yl)-methanol 3 (84 mg, 0.53 mmol, 3 
eq) was added and the reaction was allowed to return to room temp before being 
stirred overnight under an argon atmosphere. The reaction was quenched with 
water (10 mL) and extracted with DCM (3 x 10 ml). The resulting organic layer 
was dried over MgSO4 before the solvent was removed under reduced pressure. 
The resulting residue was purified by column chromatography eluting with 
EtOAc/Pet Ether (6:4 to 8:2) to yield a beige solid. (51 mg, 63% yield) 1H NMR 
(500 MHz, CDCl3) σ 8.56 (brs, 1H, NH), 8.5 (d, 1H, J = 7.4Hz), 8.3 (d, 1H, J = 
2.3Hz), 8.16 (d, 1H, J = 8.3Hz), 7.75 (t, 1H, J = 7.5Hz), 7.32 (s, 1H), 7.08 (s, 1H), 
5.31 (s, 2H), 4.16 (t,2H, J = 7.6Hz), 4.11 (s, 3H), 1.7 (qu, 2H, J = 7.4), 1.44 (sex, 
2H, J = 7.5), 0.97 (t, 3H, J = 7.4Hz). 13C NMR (125 MHz, CDCl3): 163.86, 163.60, 
153.36, 146.62, 138.24, 134.01, 133.55, 132.60, 129.46, 129.38, 128.18, 124.24, 
123.63, 123.36, 122.36, 120.12, 56.06, 34.79, 30.10, 20.27, 14.20; HRMS (ESI): 
Calculated for C22H22O6N5 [M+H]
+, expected: 452.1543, observed: 452.1562, 
PPM: -4.76; max (film)/cm-1: 3414.37, 2960.13, 1738.57, 1699.25, 1655.81, 
1626.98, 1562.83, 1490.27, 1467.33, 1432.17, 1345.74, 1272.53, 1226.28, 
1176.74, 1135.72, 1067.69, 1037.12, 837.81, 783.86. MP: 212 oC. 
 
 
4-nitro-N-butyl-1,8-naphthalimide (44) 
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4-nitro-1,8-naphthalic anhydride (1 g, 4.1 mmol, 1 eq.) and butyl amine (0.31 g, 
0.406 ml, 4.1 mmol 1 eq.) were dissolved in EtOH (17 mL) before being heated at 
110 oC for 1 hr under microwave irradiation. The mixture was allowed to cool to 
room temperature before the solvent was removed under reduced pressure. The 
resulting residue was purified by column chromatography eluting with DCM. The 
purified product was isolated as a cream solid (1.18 g, 95% yield). 1H NMR (500 
MHz, DMSO-d6) σ 8.58 (dd, 1H, J = 8.65/0.84Hz), 8.51 (dd, 1H, J = 7.34/0.8Hz), 
8.48 (d, 1H, J = 8.1Hz), 8.46 (t, 1H, J = 7.8Hz), 7.99 (dd, 1H, J = 7.62/0.86Hz), 
3.98 (t, 2H, J = 7.58Hz), 1.59 (qu, 2H, J = 7.45Hz), 1.35 (sex, 2H, J = 7.42Hz), 
0.92 (t, 3H, J = 7.42Hz). 13C NMR (500 MHz, DMSO-d6): 163.24, 162.44, 149.39, 
132.06, 130.50, 129.99, 129.09, 128.60, 126.89, 124.68, 123.05, 122.99, 29.91, 
20.25, 14.15; HRMS (ESI): Calculated for C16H15N2O4 [M+H]
+, expected: 
299.1025, observed: 299.1026, PPM: -0.4; max (film)/cm-1: 3106.27, 3069.79, 
3040.62, 2961.54, 2873.57, 1949.06, 1708.53, 1654.57, 1623.75, 1583.15, 
1529.35, 1461.93, 1439.21, 1408.28, 1346.72, 1269.49, 1231.81, 1188.64, 
1082.40. MP: 104~108 oC. 
 
 
 
4-amino-N-butyl-1,8-naphthalimide (45)  
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4-nitro-N-butyl-1,8-naphthalimide (1.1g, 3.7 mmol, 1 eq.) was dissolved in MeOH 
(70 ml) before Pd/C (0.25 g) was added and the reaction was placed under an 
atmosphere of H2. The reaction was allowed to proceed for 2 hrs before being 
filtered through a pad of celite. The solvent was removed under reduced pressure 
to yield a bright yellow solid. (1.02 g, 95% yield) 1H NMR (500 MHz, DMSO-d6) 
σ 8.59 (dd, 1H, J = 8.45/0.89Hz), 8.41 (dd, 1H, J = 7.33/0.85Hz), 8.18 (d, 1H, J = 
8.4Hz), 7.63 (dd, 1H, J = 7.48/0.83Hz), 7.43 (s, 2H), 6.82 (d, 1H, J = 8.4Hz), 3.99 
(t, 2H, J = 748Hz), 1.56 (qu, 2H, J = .48Hz), 1.31 (sex, 2H, J = 7.48Hz), 0.9 (t, 3H, 
J = 7.48Hz); 13C NMR (125 MHz, DMSO-d6): 163.94, 163.40, 153.86, 140.79, 
133.47, 132.13, 131.46, 129.74, 129.51, 128.80, 126.99, 124.48, 122.76, 117.91, 
56.48, 34.82, 30.14, 20.28, 14.21; HRMS (ESI): Calculated for C16H17N2O2 
[M+H]+, expected: 269.1273, observed: 269.1285, PPM: -4.33; max (film)/cm-1: 
3410.38, 3356.55, 3254.13, 2957.81, 2930.08, 2861.62, 1676.07, 1636.78, 
1613.97, 1575.31, 1528.50, 1480.40, 1431.25, 1378.83, 1362.04, 1304.33, 
1244.87, 1115.97, 1077.63. MP: 178~186 oC. 
 
 
(2-Butyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)-carbamic acid 
3-methyl-2-nitro-3H-imidazol-4-ylmethyl ester (28)  
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4-amino-N-butyl-1,8-naphthalimide (48 mg, 0.18 mmol, 1 eq.) and DMAP (66 mg, 
0.54 mmol, 3 eq.) were dissolved in anhydrous DCM (20 mL) and placed under 
an argon atmosphere. The reaction was cooled to -10°C using an ice and salt bath 
before phosgene solution (15 wt. % in toluene; 0.7 ml, 1.07 mmol, 6 eq.) was added 
dropwise and the reaction mixture was allowed warm to room temperature and 
stirred for 4 hrs. The reaction mixture was reduced to dryness by bubbling with 
argon before the residue was redissolved in anhydrous DCM and cooled to 0 °C 
(20 mL). (3-Methyl-2-nitro-3H-imidazol-4-yl)-methanol 3 (84 mg, 0.53 mmol, 3 
eq) was added and the reaction was allowed to return to room temp before being 
stirred overnight under an argon atmosphere. The reaction was quenched with 
water (10 mL) and extracted with DCM (3 x 10 ml). The resulting organic layer 
was dried over MgSO4 before the solvent was removed under reduced pressure. 
The resulting residue was purified by column chromatography eluting with 
EtOAc/Pet Ether (6:4 to 8:2) to yield a beige solid (55 mg, 68% yield). 1H NMR 
(500 MHz, DMSO-d6) σ 10.45 (Bs, NH), 8.67 (dd, 1H, J = 8.59/1.0Hz), 8.5 (dd, 
1H, J = 7.26/0.9Hz), 8.48 (d, 1H, J = 8.24Hz), 8.17 (d, 1H, J = 8.27Hz), 7.84 (dt, 
1H, J = 7.38/1.2Hz), 7.36 (s,1H), 5.39 (s, 2H), 4.02 (t,2H, J = 7.74Hz), 4.01 (s, 
3H), 1.6 (qu, 2H, J = 7.5Hz), 1.34 (sex, 2H, J = 7.48Hz), 0.92 (t, 3H, J = 7.47Hz); 
13C NMR (500 MHz, DMSO-d6): 163.94, 163.40, 153.86, 140.79, 133.47, 132.13, 
131.46, 129.74, 129.51, 128.80, 126.99, 124.48, 122.76, 117.91, 56.48, 34.82, 
30.14, 20.28, 14.21; HRMS (ESI): Calculated for C22H22O6N5 [M+H]
+, expected: 
452.1536, observed: 452.1565, PPM: -6.26; max (film)/cm-1: 3444.50, 3234.96, 
2928.75, 2870.81, 1698.32, 1654.59, 1592.32, 1542.07, 1486.61, 1390.09, 
1358.23, 1228.60, 1181.95. MP: 230~242 oC. 
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(2-Butyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)-carbamic acid 
4-nitro-benzyl ester (31)  
 
                                                          
4-amino-N-butyl-1,8-naphthalimide (60 mg, 0.22 mmol, 1 eq.) and DMAP (82 mg, 
0.67 mmol, 3 eq.) were dissolved in anhydrous DCM (20 mL) and placed under 
an argon atmosphere. The reaction was cooled to -10°C using an ice and salt bath 
before phosgene solution (15 wt. % in toluene; 1.0 ml, 1.33 mmol, 6 eq.) was added 
dropwise and the reaction mixture was allowed warm to room temperature and 
stirred for 4 hrs. The reaction mixture was reduced to dryness by bubbling with 
argon before the residue was redissolved in anhydrous DCM and cooled to 0 °C 
(20 mL). 4-nitrobenzyl alcohol (103 mg, 0.67 mmol, 3 eq.) was added and the 
reaction was allowed to return to room temp before being stirred overnight under 
an argon atmosphere. The reaction was quenched with water (10 mL) and was 
extracted with DCM (3 x 10 ml). The resulting organic layer was dried over 
MgSO4 before the solvent was removed under reduced pressure. The resulting 
residue was purified by column chromatography eluting with MeOH/DCM (0:100 
to 4:96) to yield a beige solid (60 mg, 60% yield). 1H NMR (500 MHz, DMSO-
d6) σ 10.50 (s, NH), 8.74 (d, 1H, J = 8.68Hz), 8.54 (d, 1H, J = 7.28Hz), 8.5 (d, 1H, 
J = 8.29Hz), 8.3 (d, 2H, J = 8.46Hz), 8.2 (d, 1H, J = 8.1Hz), 7.87 (t, 1H, J = 7.83Hz), 
7.78 (d, 2H, 8.47Hz), 4.08 (dd, 2H, 5.24Hz), 4.05 (t, 2H, 7.42Hz), 1.63 (qu, 2H, J 
= 7.51Hz), 1.36 (sex, 2H, J = 7.77Hz), 0.94 (t, 3H, J = 7.4Hz). 13C NMR (125 
MHz, DMSO-d6): 163.96, 163.41, 147.66, 144.66, 132.15, 131.43, 129.07, 126.94, 
124.13, 65.76, 55.38, 49.07, 40.61, 30.16, 20.28, 14.29. HRMS (ESI): Calculated 
for C24H21N3O6 [M+H]
+, expected: 447.1435, observed: 447.143, PPM: 0.95; max 
(film)/cm-1: 3309.52, 2956.91, 2872.62, 1707.63, 1694.55, 1646.75, 1621.35, 
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1593.24, 1544.41, 1518.43, 1447.13, 1393.43, 1365.32, 1346.34, 1224.021065.63. 
MP: 240~244 oC. 
 
 
(5-nitrothiophen-2-yl)methanol (46) 
 
                                                        
A solution of 5-nitrothiophene-2-carbaldehyde (1.05g, 1 mmol, 1 eq) and 
methanol (10 ml) was stirred at 0 °C with ice bath. Sodium borohydride (0.446 g, 
1.5 mmol, 1,5 eq) was added slowly. The mixture was stirred overnight at room 
temperature. Solvent was removed by vacuo, then water (20 ml) was added. The 
resulting mixture was extracted with DCM (3 * 30 ml). The extracts were washed 
with water (3 * 30 ml) and brine (3 * 30 ml). Dried the organic layer with MgSO4 
and removed the solvent to yield a black liquid (0.703 g, 67% yield). 1H NMR 
(500 MHz, Chloroform-d) σ 7.793 (d, 1 H, J = 4.15 Hz), 6.91 (d, 1 H, J = 4.12 Hz), 
4.855 (d, 2 H, J = 2.56 Hz); 13C NMR (125 MHz, Chloroform-d): 153.7632, 
150.7806, 128.7298, 123.4825, 60.4389; HRMS (ESI): Calculated for C5H5NO3S 
[M+H]+, expected: 158.999, observed: 158.9983, PPM: -4.63; max (film)/cm-1: 
3846.95, 3400.52, 3107.59, 2929.12, 2871.4, 2666.33, 2461.46, 2374.99, 2304.62, 
2162.18, 2071.44, 1809.39, 1678.80, 1634.44, 1206.63, 1160.27. 
 
 
(5-nitrothiophen-2-yl)methyl(2-butyl-1,3-dioxo-2,3-dihydro-1H-
benzo[de]isoquinolin-6-yl)carbamate (32) 
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4-amino-N-butyl-1,8-naphthalimide (60 mg, 0.224 mmol, 1 eq.) and DMAP 
(82.11 mg, 0.672 mmol, 3 eq.) were dissolved in anhydrous DCM (20 mL) and 
placed under an argon atmosphere. The reaction was cooled to -10°C using an ice 
and salt bath before phosgene solution (15 wt. % in toluene; 1.0 ml, 1.33 mmol, 6 
eq.) was added dropwise and the reaction mixture was allowed warm to room 
temperature and stirred for 4 hrs. The reaction mixture was reduced to dryness by 
bubbling with argon before the residue was redissolved in anhydrous DCM and 
cooled to 0 °C (20 mL). (5-nitrothiophen-2-yl)methanol (107 mg, 0.672 mmol, 3 
eq.) was added and the reaction was allowed to return to room temp before being 
stirred overnight under an argon atmosphere. The reaction was quenched with 
water (10 mL) and was extracted with DCM (3 x 10 ml). The resulting organic 
layer was dried over MgSO4 before the solvent was removed under reduced 
pressure. The resulting residue was purified by column chromatography eluting 
with EtOAc/Pet Ether (1:1) to yield a beige solid (63 mg, 63% yield). ). 1H NMR 
(500 MHz, DMSO-d6) σ 8.64 (d, 1 H, J = 7.16 Hz), 8.61 (d, 1 H, J = 8.12 Hz), 8.32 
(d, 1 H, J = 8.46 Hz), 8.17 (d, 1 H, J = 8.19 Hz), 7.83 (d, 1 H, J = 3.57 Hz), 7.79 
(t, 1 H, J = 7.52 Hz), 7.47(s, NH), 7.125 (d, 1 H, J = 3.93 Hz), 4.17 (t, 2 H, J = 7.48 
Hz), 1.71 (qu, 2 H, J = 7.02 Hz), 1.44 (sex, 2 H, J = 7.34 Hz), 0.97 (t, 3 H, J = 7.06 
Hz); 13C NMR (125 MHz, DMSO-d6): 164.027, 163.553, 145.08, 138.00, 132.28, 
131.362, 128.211, 127.351, 126.924, 125.663, 123.65, 118.716, 61.69, 40.29, 
30.218, 20.39, 13.8376; HRMS (ESI): Calculated for C22H19N3O6S [M+H]
+, 
expected: 453.0995, observed: 453.0999, PPM: 1.07; max (film)/cm-1: 3328.62, 
3063.72, 2960.44, 1711.21, 1694.5, 1621.04, 1593.16, 1553.99, 1510.99, 1445.63, 
1394.59, 1346.39, 1244.32, 1225.71. 
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(2-Amino-ethyl)-carbamic acid tert-butyl ester (51) [65] 
 
                                                            
To a 250 ml of round bottom flask was added ethyl diamine (13.4Ml, 200mmol) 
in CHCl3 (100Ml). A solution of Di-tert-butyl dicarbonate (4.4 g, 20mmol) in 
CHCl3 (50 ml) was added dropwise over 2 hours at 0 oC. Stirred at RT for 24 hours. 
The mixture was washed with brine. The organic layer was washed with H2O. 
dried with MgSO4 and concentrated in vacuum to yield a colorless liquid (2.89 g, 
90% yield). 1H NMR (500 MHz, DMSO-d6) σ 7.417 (s, NH), 5.49 (s, NH), 3.156 
(d, 2 H, J = 5.37 Hz), 2.786 (t, 2 H, J = 5.91 Hz), 1.44 (s, 9 H); 13C NMR (125 
MHz, DMSO-d6): 156.2326, 78.8123, 77.456, 77.4, 77.2, 76.94, 68.34; HRMS 
(ESI): Calculated for C7H16O2N2  [M+H]+, expected: 160.1217, observed: 
160.1212, PPM: 2.99. 
 
 
[2-(6-Nitro-1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-ethyl]-carbamic acid 
tert-butyl ester (52) 
                     
4-nitro-1,8-naphthalic anhydride (0.4 g, 1.65 mmol, 1 eq.) and (2-Amino-ethyl)-
carbamic acid tert-butyl ester (0.263 g, 263 ul, 1.65 mmol, 1 eq.) were dissolved 
in EtOH (14 mL) before being heated at 110 oC for 1 hr under microwave 
irradiation. The mixture was allowed to cool to room temperature before the 
solvent was removed under reduced pressure. The resulting residue was purified 
by column chromatography eluting with pure dichloromethane to 3% methanol in 
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dichloromethane. The purified product was isolated as a cream yellow solid (0.566 
g, 86.01% yield). 1H NMR (500 MHz, DMSO-d6) σ 8.846 (d, 1 H, J = 8.9 Hz), 
8.749 (d, 1 H, J = 7.29 Hz), 8.705 (d, 1 H, J = 7.95 Hz), 8.4 (d, 1 H, J = 8.09 Hz), 
7.98 ( t, 1 H, J = 8.49 Hz), 4.85 (s, NH), 4.37 (t, 2 H, J = 5.35 Hz), 3.55 (d, 2 H, J 
= 5.14 Hz), 1.237 (s, 9 H); 13C NMR (125 MHz, DMSO-d6): 136.6366, 156.2874, 
149.5733, 132.0410, 130.5680, 129.0647, 128.9660, 124.6667, 123.1953, 77.9744, 
38.0379, 28.5142; HRMS (ESI): Calculated for C19H19O6N3  [M+H]+, expected: 
385.1276, observed: 385.1274, PPM: 0.56; max (film)/cm-1: 3400.79, 3070.24, 
2977.06, 2935.65, 1719.09, 1701.93, 1623.19, 1583.90, 1524.01, 1447.90, 
1410.74, 1366.32, 1341.39, 1272.94, 1233.68, 1192.60. 
 
 
 
[2-(6-Amino-1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-ethyl]-carbamic 
acid tert-butyl ester (53) 
 
                                                          
[2-(6-Nitro-1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-ethyl]-carbamic acid 
tert-butyl ester (0.4g, 1.038 mmol, 1 eq.) was dissolved in MeOH (70 ml) before 
Pd/C (0.2 g) was added and the reaction was placed under an atmosphere of H2. 
The reaction was allowed to proceed for 4 hrs before being filtered through a pad 
of celite. The solvent was removed under reduced pressure to yield a mustard solid 
(0.33 g, 90% yield). 1H NMR (500 MHz, DMSO-d6) σ 8.604 (d, 1 H, J = 8.39 
Hz), 8.42 (d, 1 H, J = 7.05 Hz), 8.191 (d, 1 H, J = 8.39 Hz), 7.6539 (t, 1 H, J = 7.59 
Hz), 7.3839 (s, 2 NH), 6.84 (d, 1 H, J = 8.47 Hz), 4.097 (t, 2 H, J = 5.95 Hz), 3.22 
(q, 2 H, J = 6.2 Hz), 1.379 (s, NH), 1.2683 (s, 9 H); 13C NMR (125 MHz, DMSO-
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d6): 164.4716, 163.5858, 156.1299, 152.9727, 134.2628, 131.2949, 130.3129, 
129.5576, 124.3589, 122.5508, 119.8571, 108.5024, 108.4046, 77.8726, 38.5433, 
28.6136; HRMS (ESI): Calculated for C19H21O4N3  [M+H]+, expected: 355.1557, 
observed: 355.1532, PPM: 7.07; max (film)/cm-1: 3366.18, 3257.63, 2976.80, 
1701.80, 1677.65, 1659.51, 1634.51, 1528.80, 1480.76, 1447.57, 1427.25, 
1368.58, 1273.04, 1246.82, 1170.18. 
 
 
[2-(2-tert-Butoxycarbonylamino-ethyl)-1,3-dioxo-2,3-dihydro-1H-
benzo[de]isoquinolin-6-yl]-carbamic acid 5-methyl-4-nitro-cyclopenta-1,3-
dienylmethyl ester (34) 
 
                                                 
[2-(6-Amino-1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-ethyl]-carbamic acid 
tert-butyl ester (53.27 mg, 0.15 mmol, 1 eq.) and DMAP (54.9 mg, 0.45 mmol, 3 
eq.) were dissolved in anhydrous DCM (20 mL) and placed under an argon 
atmosphere. The reaction was cooled to -10°C using an ice and salt bath before 
phosgene solution (15 wt. % in toluene; 0.6 ml, 0.9 mmol, 6 eq.) was added 
dropwise and the reaction mixture was allowed warm to 0°C and stirred for 4 hrs. 
The reaction mixture was reduced to dryness by bubbling with argon before the 
residue was redissolved in anhydrous DCM and cooled to 0 °C (20 mL). (3-
Methyl-2-nitro-3H-imidazol-4-yl)-methanol (70.7 mg, 0.45 mmol, 3 eq) was 
added and the reaction was allowed to return to room temp before being stirred 
overnight under an argon atmosphere. The reaction was quenched with water (10 
mL) and extracted with DCM (3 x 10 ml). The resulting organic layer was dried 
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over MgSO4 before the solvent was removed under reduced pressure. The resulting 
residue was purified by column chromatography eluting with 
Methanol/Dichloromethane (0:100 to 5:95) to yield a beige solid (35 mg, 43.7% 
yield). . 1H NMR (500 MHz, DMSO-d6) σ 10.4 (s, NH), 8.677 (d, 1 H, J = 8.8 
Hz), 8.5 (d, 1 H, J = 7.33 Hz), 8.48 (d, 1 H, J = 8.01 Hz), 8.1667 (d, 1 H, J = 8.13 
Hz), 7.84 (t, 1 H, J = 7.65 Hz), 7.37 (s, NH), 6.868 (t, 1 H, J = 6.72 Hz), 5.4 (s, 2 
H), 4.133 (t, 2 H, J = 6.13 Hz), 4.03 (s, 3 H), 3.26 (q, 2 H, J = 5.81 Hz), 1.223 (s, 
9 H); 13C NMR (125 MHz, DMSO-d6): 164.18, 163.63, 156.24, 153.92, 146.62, 
133.52, 131.89, 131.24, 129.53, 129.47, 128.97, 126.85, 123.04, 119.07, 77.92, 
56.46, 39.45, 38.25, 34.80, 28.52; HRMS (ESI): Calculated for C25H26O8N6  
[M+H]+, expected: 538.1821, observed: 538.1812, PPM: 1.67; max (film)/cm-1: 
3386.43, 2977.00, 1742.88, 1690.60, 1654.27, 1592.06, 1547.60, 1496.41, 
1427.17, 1387.29, 1368.27, 1352.74, 1242.34, 1204.44. 
 
 
(3-Amino-propyl)-triphenyl-phosphonium (54) 
 
                                                              
3-Bromo-propylamine (1.25 g, 5.719 mmol, 1 eq) and Triphenyl-phosphane (1.5 
g, 5.719 mmol, 1 eq) were refluxed in acetonitrile ( 40 ml) for 24 hours. After the 
reaction, a white precipitate formed. Cooled down to RT and filtered the solid 
which was washed with dichloromethane ( 3 x 10 ml). finally yield a white solid. 
(0.849 g, 46.4% yield). 1H NMR (500 MHz, DMSO-d6) σ 7.94 (m, 3 H), 7.81 (m, 
12 H), 7.66 (s, 2 NH), 3.669 (t, 2 H, J = 15.37 Hz), 2.96 (t, 2 H, J = 7.93 Hz), 1.81 
(sex, 2 H, J = 7.8 Hz); 13C NMR (125 MHz, DMSO-d6): 135.6313, 135.6077, 
134.1169, 134.0355, 130.9202, 130.8206, 118.8527, 118.1672, 20.6346, 18.9292, 
18.5066; HRMS (ESI): Calculated for C21H23NP  [M+H]+, expected: 320.1556, 
observed: 320.1568, PPM: -3.82; max (film)/cm-1: 3417.28, 2817.28, 2742.44, 
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2064.51, 1612.05, 1586.92, 1518.01, 1481.96, 1434.32, 1398.16, 1314.84, 
1156.16, 1110.91, 995.27. 
 
 
6-Nitro-2-[3-(triphenyl-l5-phosphanyl)-propyl]-benzo[de]isoquinoline-1,3-
dione (55) 
 
 
                                                   
(3-Amino-propyl)-triphenyl-phosphonium (0.235 g, 0.734 mmol, 1 eq.) and 4-
nitro-1,8-naphthalic anhydride (0.179 g, 0.734 mmol, 1 eq.) and trimethylamine 
(204.3 ul, 1.468 mmol, 2 eq) were dissolved in EtOH (14 mL) before being heated 
at 110 oC for 1 hr under microwave irradiation. The mixture was allowed to cool 
to room temperature before the solvent was removed under reduced pressure. The 
resulting residue was purified by column chromatography eluting with pure 
dichloromethane to 5% methanol in dichloromethane. The purified product was 
isolated as a yellow solid ( 0.566 g, 86.01% yield). 1H NMR (500 MHz, DMSO-
d6) σ 8.37 (dd, 1 H, J = 8.61/ 0.8 Hz), 8.64 (d, 1 H, J = 7.44 Hz), 8.59 (dd, 2 H, J 
= 14.28/ 8.17 Hz), 8.114 (dd, 1 H, J = 8.09/ 1.38 Hz), 7.9 (m, 3 H), 7.77 (m, 12 H), 
4.25 (t, 2 H, J = 7.13 Hz), 3.75 (sex, 2 H, J = 5.82 Hz), 2.033 (sex, 2 H, J = 7.51 
Hz); 13C NMR (125 MHz, DMSO-d6): 163.76, 135.45, 134.14, 134.06, 132.11, 
130.78, 130.68, 130.6, 130.0, 127.37, 124.67, 123.51, 119.08, 118.4, 9.33; HRMS 
(ESI): Calculated for C33H26O4N2P  [M+H]+, expected: 545.1598, observed: 
545.163, PPM: -5.89; max (film)/cm-1: 3422.11, 2936.96, 2677.07, 1705.43, 
1664.94, 1585.8, 1526.05, 1437.82, 1345.84, 1250.93, 1113.21, 1033.75. 
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6-Amino-2-[3-(triphenyl-l5-phosphanyl)-propyl]-benzo[de]isoquinoline-1,3-
dione (56) 
 
                                                   
6-Nitro-2-[3-(triphenyl-l5-phosphanyl)-propyl]-benzo[de]isoquinoline-1,3-dione 
(0.4 g,  0.75 mmol, 1 eq.) was dissolved in MeOH (70 ml) before Pd/C (0.2 g) was 
added and the reaction was placed under an atmosphere of H2. The reaction was 
allowed to proceed for 4 hrs before being filtered through a pad of celite. The 
solvent was removed under reduced pressure to yield a mustard solid (0.253g, 67% 
yield). 1H NMR (500 MHz, DMSO-d6) σ 8.631 (dd, 1 H, J = 8.53/ 1.24 Hz), 8.4 
(dd, 1 H, J = 7.38/ 1.11 Hz), 8.17 (d, 1 H, J = 8.45 Hz), 7.89 (m, 3 H), 7.77 (m, 12 
H), 7.65 (t, 1 H, J = 7.87 Hz), 7.48 (s, 2H), 6.84 (d, 1 H, J = 8.34 Hz), 4.2 (t, 2 H, 
J = 7.27 Hz), 3.74 (qu, 2 H, J = 3.8 Hz), 1.96 (qu, 2 H, J = 7.89 Hz); 13C NMR 
(125 MHz, DMSO-d6): 164.46, 163.49, 135.4, 134.48, 134.16, 134.08, 131.52, 
130.74, 130.64, 130.33, 129.86, 124.43, 122.32, 119.84, 119.14, 118.45, 108.61, 
107.98; HRMS (ESI): Calculated for C33H28O2N2P  [M+H]+, expected: 515.1862, 
observed: 515.1888, PPM: -5.05; max (film)/cm-1: 3420.05, 3161.39, 1678.30, 
1637.77, 1583.40, 1528.98, 1481.68, 1437.97, 1380.78, 1363.33, 1307.61, 
1251.00, 1113.46. 
 
 
{1,3-Dioxo-2-[3-(triphenyl-l5-phosphanyl)-propyl]-2,3-dihydro-1H-
benzo[de]isoquinolin-6-yl}-carbamic acid 3-methyl-2-nitro-3H-imidazol-4-
ylmethyl ester (35) 
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6-Amino-2-[3-(triphenyl-l5-phosphanyl)-propyl]-benzo[de]isoquinoline-1,3-
dione (77.25 mg, 0.15 mmol, 1 eq.) and DMAP (54.98 mg, 0.45 mmol, 3 eq.) were 
dissolved in anhydrous DCM (20 mL) and placed under an argon atmosphere. The 
reaction was cooled to -10°C using an ice and salt bath before phosgene solution 
(15 wt. % in toluene; 0.6 ml, 0.9 mmol, 6 eq.) was added dropwise and the reaction 
mixture was allowed warm to 0°C and stirred for 4 hrs. The reaction mixture was 
reduced to dryness by bubbling with argon before the residue was redissolved in 
anhydrous DCM and cooled to 0 °C (20 mL). (3-Methyl-2-nitro-3H-imidazol-4-
yl)-methanol (70.7 mg, 0.45 mmol, 3 eq) was added and the reaction was allowed 
to return to room temp before being stirred overnight under an argon atmosphere. 
The reaction was quenched with water (10 mL) and extracted with DCM (3 x 10 
ml). The resulting organic layer was dried over MgSO4 before the solvent was 
removed under reduced pressure. The resulting residue was purified by column 
chromatography eluting with Methanol/Dichloromethane (0:100 to 5:95) to yield 
a beige solid (17 mg, 16.3% yield). 1H NMR (500 MHz, DMSO-d6) σ  10.23 (s, 
NH), 8.63 (dd, 1 H, J = 7.64/1.02 Hz), 8.40 (dd, 1 H, J = 6.47/0.75 Hz), 8.38 (d, 1 
H, J = 8.23 Hz), 8.15 (d, 1 H, J = 8.34 Hz), 8.13 (d, 2 H, J = 6.78 Hz), 7.88 (m, 3 
H), 7.76 (M, 12 H), 6.70 (dd, 2 H, J = 1.48/3.85 Hz), 4.299 (t, 2 H, J = 5.56 Hz), 
4.20 (t, 2 H, J = 6.99 Hz), 3.75 (qu, 2 H, J = 6.79 Hz), 1.985 (t, 3 H, J = 4.89 Hz); 
13C NMR (125 MHz, DMSO-d6): 163.03, 162.388, 154.511, 153.981, 144.486, 
134.085, 132.703, 132.624, 130.769, 129.565, 129.465, 124. 668, 117.581, 
116.896, 114.66, 105.57, 49.75, 38.44, 24.97; HRMS (ESI): Calculated for 
C39H33O6N5P  [M+H]+, expected: 698.2169, observed: 698.2241, PPM:1.03; 
max (film)/cm-1: 3416.92, 2923.49, 1726.22, 1693.35, 1650.65, 1587.65, 
1542.51, 1438.09, 1391.55, 1363.68, 1212.60, 1108.33. 
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6-(6-Nitro-1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid (57) 
 
                                                    
6-Amino-hexanoic acid (0.404 g, 3.084 mmol, 1 eq.) and 4-nitro-1, 8-naphthalic 
anhydride (0.75 g, 3.084 mmol, 1 eq.) were dissolved in EtOH (15 mL) before 
being heated at 110 oC for 1 hr under microwave irradiation. The mixture was 
allowed to cool to room temperature before the solvent was removed under 
reduced pressure. The resulting residue was purified by column chromatography 
eluting with pure dichloromethane to 5% methanol in dichloromethane. The 
purified product was isolated as an orange solid (0.9743 g, 88.74% yield). 1H 
NMR (500 MHz, DMSO-d6) σ 8.84 (d, 1 H, J = 8.72 Hz), 8.74 (d, 1 H, J = 7.38 
Hz), 8.695 (d, 1 H, J = 8.13 Hz), 8.409 (d, 1 H, J = 7.89 Hz), 7.992 (t, 1 H, J = 7.89 
Hz), 4.196 (t, 2 H, J = 7.196 Hz), 2.38 (t, 2 H, J = 7.38 Hz), 1.75 (m, 4 H), 1.495 
(qu, 2 H, J = 7.72); 13C NMR (125 MHz, DMSO-d6): 163.3252, 162.5042, 
149.6122, 132.4993, 129.9637, 129.8619, 139.3619, 129.1181, 126.981, 123.9221, 
123.7088, 123.0075, 40.542, 27.6088, 26.4552, 24.3196; ; HRMS (ESI): 
Calculated for C18H16O6N2  [M+H]+, expected: 379.0901, observed: 379.0984, 
PPM: 2.91; max (film)/cm-1: 3078.02, 2943.60, 2865.89, 1703.30, 1624.88, 
1593.97, 1583.18, 1521.67, 1460.75, 1437.15, 1410.20, 1339.84, 1261.87, 
1230.39, 1182.72, 1157.54, 1121.24, 1079.16. 
 
 
6-(6-Amino-1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid (58) 
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6-(6-Nitro-1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid (07.g,  
1.9662 mmol, 1 eq.) was dissolved in MeOH (45 ml) before Pd/C (0.2 g) was 
added and the reaction was placed under an atmosphere of H2. The reaction was 
allowed to proceed for 4 hrs before being filtered through a pad of celite. The 
solvent was removed under reduced pressure to yield a brownish red solid ( 0.6 g, 
93.75 % yield). 1H NMR (500 MHz, DMSO-d6) σ 8.618 (d, 1 H, J = 8.48 Hz), 
8.434 (d, 1 H, J = 7.07 Hz), 8.198 (d, 1 H, J = 8.48 Hz), 7.66 (t, 1 H, J = 7.46Hz), 
7.441 (s, 2 NH), 6.849 (d, 1 H, J = 8.5 Hz), 3.997 (t, 2 H, J = 7.48 Hz), 2.21 (t, 2 
H, J = 7.48 Hz), 1.6 (qu, 2 H, J = 7.4 Hz), 1.54 (qu, 2 H, J = 7.4 Hz), 1.32 (qu, 2 
H, J = 8.07 Hz); 13C NMR (125 MHz, DMSO-d6): 174.9314, 164.2348, 163.3670, 
153.171, 134.4343, 131.4837, 130.1530, 129.7605, 124.4667, 122.2607, 119.8384, 
108.6363, 108.0192, 34.0072, 27.9025, 26.5495, 24.7321; HRMS (ESI): 
Calculated for C18H18O4N2  [M+H]+, expected: 326.1262, observed: 326.1267, 
PPM: -1.52; max (film)/cm-1: 3429.86, 3358.01, 3243.00, 2949.90, 2855.03, 
1750.98, 1651.27, 1623.59, 1606.81, 1532.14, 1482.77, 1454.40, 1432.92, 
1376.46, 1310.12, 1248.28. 
 
 
 
6-[6-(3-Methyl-2-nitro-3H-imidazol-4-ylmethoxycarbonylamino)-1,3-dioxo-
1H,3H-benzo[de]isoquinolin-2-yl]-hexanoic acid (33) 
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6-(6-Amino-1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid (48.918 
mg, 0.15 mmol, 1 eq.) and DMAP (54.98 mg, 0.45 mmol, 3 eq.) were dissolved in 
anhydrous DCM (20 mL) and placed under an argon atmosphere. The reaction was 
cooled to -10°C using an ice and salt bath before phosgene solution (15 wt. % in 
toluene; 0.6 ml, 0.9 mmol, 6 eq.) was added dropwise and the reaction mixture was 
allowed warm to 0°C and stirred for 4 hrs. The reaction mixture was reduced to 
dryness by bubbling with argon before the residue was redissolved in anhydrous 
DCM and cooled to 0 °C (20 mL). (3-Methyl-2-nitro-3H-imidazol-4-yl)-methanol 
(70.7 mg, 0.45 mmol, 3 eq) was added and the reaction was allowed to return to 
room temp before being stirred overnight under an argon atmosphere. The reaction 
was extracted with DCM (3 x 10 ml). The resulting organic layer was dried over 
MgSO4 before the solvent was removed under reduced pressure. The resulting 
residue was purified by HPLC Technique eluting with water/acetonitrile from 1 : 
0 to 0 : 1 to yield the pare yellow solid (7 mg, 9.1% yield)  1H NMR (500 MHz, 
DMSO-d6) σ 8.68 (dd, 1 H, J = 8.61/1.03 Hz), 8.52 (dd, 1 H, J = 7.28/1.03 Hz), 
8.5 (d, 1 H, J = 8.3 Hz), 8.18 (d, 1 H, J = 8.08 Hz), 7.85 (dd, 1 H, J = 1.17/7.4 Hz), 
7.37 (s, 1 H), 5.41 (s, 2 H), 4.035 (t, 2 H, J = 7.17 Hz), 4.03 (s, 3 H), 1.64 (qu, 2 
H, J = 7.68 Hz), 1.55 (qu, 2 H, J = 7.87 Hz), 1.35 (qu, 2 H, J = 8.56 Hz) ); 13C 
NMR (125 MHz, DMSO-d6): 163.39, 157.39, 139.46, 139.14, 133.49, 129.48, 
129.15, 128.65, 127.06, 107.41, 55.37, 53.39, 34.84, 34.61, 34.58, 33.48, 26.28, 
24.49; HRMS (ESI): Calculated for C24H23O8N5  [M+H]+, expected: 509.1539, 
observed: 509.1547, PPM: -1.46; max (film)/cm-1: 3410.26, 3347.58, 3101.01, 
2953.86, 1740.33, 1701.24, 1690.50, 1592.41, 1487.64, 1377.63, 1369.72, 
1354.60, 1245.35, 1205.34 
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2-Amino-3-methyl-3H-imidazole-4-carboxylic acid ethyl ester (39) 
 
                                                       
30 ml of Ethyl formate was added to 100 ml round bottle flask with sarcosine ethyl 
ester hydrochloride (2 g, 13.01 mmol, 1 eq) in it. Slowly added potassium tert 
butoxide (2.19 g, 19.53 mmol, 1.5 eq) to flask for 0.5 hr and stirred for 2 hr at 
room temperature. In addition, potassium tert-butoxide (2.91 g, 26.04 mmol, 2 eq) 
was added at 10 C for 2 hr. 30 ml of brine and 10 ml of toluene were added. Mixed 
and filtered the aqueous layer, which was washed with toluene (10 ml * 2) to 
remove Ethyl formate. 5.5 ml of conc HCl and Ethylene glycol (3.5 g, 19.515 
mmol, 1.5 eq) were added, stirred for 1 hr at 58 C. Sodium acetate (8 g, 97.5 mmol, 
7.49 eq) was added in the flask to adjust the ph to 4.5. Cyanamide (1.09 g, 26.02 
mmol, 2 eq) was added and the reaction was stirred for 2 hr at 87 C. After the 
reaction, cool down the solvent with ice bath. 30% Sodium hydroxide solution was 
used to adjust the ph to 9. Keep the solution for 10 mins and then filtered the solid 
to yield pare yellow compound (1.45 g, 66.2 % yield). 1H NMR (500 MHz, 
DMSO-d6) σ 7.28 (s, 1 H), 6.1889 (S, 2 NH), 4.156 (q, 2 H, J = 7.12 Hz), 3.5258 
(s, 3 H), 1.239 (t, 3 H, J = 7.12 Hz); 13C NMR (125 MHz, DMSO-d6): 160.2032, 
154.8042, 136.5759, 117.3921, 59.3449, 30.6925, 14.8355; HRMS (ESI): 
Calculated for C7H11O3N2  [M+H]+, expected: 169.0851, observed: 169.0851, 
PPM: 0.01; max (film)/cm-1: 3394.02, 3133.32, 2987.61, 1547.62, 1480.84, 
1460.16, 1380.70, 1349.74, 1304.94, 1247.22, 1213.03, 1172.40, 1127.78, 
1110.33. 
 
 
 
3-Methyl-2-nitro-3H-imidazole-4-carboxylic acid ethyl ester (40) 
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To an aqueous solution of sodium nitrite (6 ml, 4.08 g, 59.2 mmol, 10 eq) was 
added aminoimodazole (1 g, 5.92 mmol, 1 eq) in acetic acid (10 ml) in a dropwise 
manner. This reaction was stirred for 4 hr at room temperature when there was no 
nitrogen gas evolved. The organic layer was extracted with dichloromethane (2 * 
10 ml), washed with brine (1 *20 ml) and saturated aqueous solution of sodium 
sulfite (1 * 20 ml), dried with magnesium sulfate, and filtered. The filtrate was 
concentrated in vacuo, and the product was purified by silica gel column 
chromatography, eluting with dichloromethane, to yield a white crystal (0.8 g, 
69.7 % yield). 1H NMR (500 MHz, DMSO-d6) σ 7.79 (s, 1 H), 4.34 (q, 2 H, J = 
7.06 Hz), 4.188 (s, 3 H), 1.327 (t, 3 H, J = 7.14 Hz); 13C NMR (125 MHz, DMSO-
d6): 159.2626, 134.2536, 126.5996, 61.90, 55.35, 35.7, 14.45; HRMS (ESI): 
Calculated for C7H9O4N3  [M+H]+, expected: 199.0604, observed: 199.0593, PPM: 
5.7; max (film)/cm-1: 3433.14, 2984.44, 1554.60, 1521.61, 1488.95, 1422.68, 
1367.58, 1332.08, 1286.76, 1241.99, 1183.37, 1144.26, 1105.38. 
 
 
 
 
3-Methyl-2-nitro-3H-imidazole-4-carboxylic acid (41) 
 
                                                      
To 3-Methyl-2-nitro-3H-imidazole-4-carboxylic acid ethyl ester (563 mg, 2.814 
mmol, 1 eq), was added a 1 N aqueous solution of NaOH (0.6 g in 15 ml water), 
and the resulting suspension was stirred for O/N. After this time the reaction 
solution was acidified to ph 1 using conc HCl, resulting the formation of white 
precipitate. The organic compound was extracted with EtOAc (5 * 20 ml), the 
organic layers combined and dried over MgSO4, and filtered. The filterate was 
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concentrated in vacuo, to finally yield a white solid (417 mg, 87 % yield). 1H NMR 
(500 MHz, DMSO-d6) σ 7.73 (s, 1 H), 4.19 (s, 3 H); 13C NMR (125 MHz, DMSO-
d6): 160.8163, 134.1750, 127.5690, 35.5296, 34.7931; HRMS (ESI): Calculated 
for C5H5O4N3  [M+H]+, expected: 171.0264, observed: 171.028, PPM: -8.88; 
max (film)/cm-1: 3417.52, 3147.68, 2856.25, 2541.83, 1850.15, 1171.20, 
1558.62, 1522.81, 1489.13, 1435.84, 1363.41, 1328.62, 1287.35, 1247.06, 
1177.86, 1109.83. 
 
 
(3-Methyl-2-nitro-3H-imidazol-4-yl)-methanol (36) 
 
                                                      
To a 100 ml round bottom flask with anhydride THF (30 ml) at -15 C with salt/ice 
bath, was added 3-Methyl-2-nitro-3H-imidazole-4-carboxylic acid (363 mg, 2.123 
mmol, 1 eq) and trimethylamine (0.504 ml, 3.609 mmol, 1.7 eq). Isobutyl 
Chloroformate (0.44 ml, 3.396 mmol, 1.6 eq) was added dropsied during 10 min. 
The reaction was stirred for 1 hr at -15 C. Sodium borohydride (401.53 mg, 10.614 
mmol, 5 eq) was added and keep stirring for 5 min, then 15 ml water was added 
slowly (if bubble come out, then wait for a while until bubble was gone and the 
temperature back to – 5 C). Kept the reaction at 0 C for 1 hr. The reaction was 
filtered to remove the precipitate which was washed with THF. Combined the 
organic layer and then separated the aqueous layer, and dried the organic layer 
with MgSO4, and removed the solvent to yield the yellow solid (167 mg, 50.1 % 
yield). 1H NMR (500 MHz, DMSO-d6) σ 7.12 (s, 1 H), 5.499 (t, 1 H, J = 5.46 Hz), 
4.545 (dd, 2 H, J = 5.45/ 0.3 Hz), 3.92 (s, 3 H); 13C NMR (125 MHz, DMSO-d6): 
139.1334, 127.0317, 61.2139, 34.5766, 23.6741; HRMS (ESI): Calculated for 
C5H7O3N3  [M+H]+, expected: 157.0488, observed: 157.0487, PPM: 0.62; max 
(film)/cm-1: 3255.43, 2965.39, 1748.04, 1540.11, 1494.33, 1468.35, 1397.20, 
1362.13, 1331.34, 1277.34, 1242.07, 1188.88, 1124.27, 1042.72. 
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Chapter 7 Appendix 
 
 
Figure 7-1: The 1H NMR spectrum of compound 42 (500 MHz, DMSO-d6) 
 
 
Figure 7-2: The 13C NMR spectrum of compound 42 (125 MHz, DMSO-d6) 
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Figure 7-3: The 1H NMR spectrum of compound 43 (500 MHz, DMSO-d6) 
 
 
Figure 7-4: The 13C NMR spectrum of compound 43 (125 MHz, DMSO-d6) 
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Figure 7-5: The 1H NMR spectrum of compound 29 (500 MHz, CDCl3) 
 
 
Figure 7-6: The 13C NMR spectrum of compound 29 (125 MHz, CDCl3) 
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Figure 7-7: The 1H NMR spectrum of compound 44 (500 MHz, DMSO-d6) 
 
 
Figure 7-8: The 13C NMR spectrum of compound 44 (125 MHz, DMSO-d6) 
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Figure 7-9: The 1H NMR spectrum of compound 45 (500 MHz, DMSO-d6) 
 
 
Figure 7-10: The 13C NMR spectrum of compound 45 (125 MHz, DMSO-d6) 
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Figure 7-11: The 1H NMR spectrum of compound 28 (500 MHz, DMSO-d6) 
 
 
Figure 7-12: The 13C NMR spectrum of compound 28 (125 MHz, DMSO-d6) 
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Figure 7-13: The 1H NMR spectrum of compound 31 (500 MHz, DMSO-d6) 
 
 
Figure 7-14: The 13C NMR spectrum of compound 31 (125 MHz, DMSO-d6) 
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Figure 7-15: The 1H NMR spectrum of compound 46 (500 MHz, CDCl3) 
 
 
Figure 7-16: The 13C NMR spectrum of compound 46 (125 MHz, CDCl3) 
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Figure 7-17: The 1H NMR spectrum of compound 32 (500 MHz, DMSO-d6) 
 
 
Figure 7-18: The 13C NMR spectrum of compound 32 (125 MHz, DMSO-d6) 
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Figure 7-19: The 1H NMR spectrum of compound 51 (500 MHz, DMSO-d6) 
 
 
Figure 7-20: The 13C NMR spectrum of compound 51 (125 MHz, DMSO-d6) 
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Figure 7-21: The 1H NMR spectrum of compound 52 (500 MHz, CDCl3) 
 
 
Figure 7-22: The 13C NMR spectrum of compound 52 (500 MHz, CDCl3) 
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Figure 7-23: The 1H NMR spectrum of compound 53 (500 MHz, DMSO-d6) 
 
 
Figure 7-24: The 13C NMR spectrum of compound 53 (125 MHz, DMSO-d6) 
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Figure 7-25: The 1H NMR spectrum of compound 48 (500 MHz, DMSO-d6) 
 
 
Figure 7-26: The 13C NMR spectrum of compound 48 (125 MHz, DMSO-d6) 
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Figure 7-27: The 1H NMR spectrum of compound 54 (500 MHz, DMSO-d6) 
 
 
Figure 7-28: The 13C NMR spectrum of compound 54 (125 MHz, DMSO-d6) 
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Figure 7-29: The 1H NMR spectrum of compound 55 (500 MHz, DMSO-d6) 
 
 
Figure 7-30: The 13C NMR spectrum of compound 55 (125 MHz, DMSO-d6) 
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Figure 7-31: The 1H NMR spectrum of compound 56 (500 MHz, DMSO-d6) 
 
 
Figure 7-32: The 13C NMR spectrum of compound 56 (125 MHz, DMSO-d6) 
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Figure 7-33: The 1H NMR spectrum of compound 49 (500 MHz, DMSO-d6) 
 
 
Figure 7-34: The 13C NMR spectrum of compound 49 (125 MHz, DMSO-d6) 
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Figure 7-35: The 1H NMR spectrum of compound 57 (500 MHz, CDCl3) 
 
 
Figure 7-36: The 13C NMR spectrum of compound 57 (125 MHz, CDCl3) 
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Figure 7-37: The 1H NMR spectrum of compound 58 (500 MHz, DMSO-d6) 
 
 
Figure 7-38: The 13C NMR spectrum of compound 58 (125 MHz, DMSO-d6) 
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Figure 7-39: The 1H NMR spectrum of compound 50 (500 MHz, DMSO-d6) 
 
 
Figure 7-40: The 13C NMR spectrum of compound 50 (500 MHz, DMSO-d6) 
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Figure 7-41: The 1H NMR spectrum of compound 39 (500 MHz, DMSO-d6) 
 
 
Figure 7-42: The 13C NMR spectrum of compound 39 (125 MHz, DMSO-d6) 
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Figure 7-43: The 1H NMR spectrum of compound 40 (500 MHz, DMSO-d6) 
 
 
Figure 7-44: The 13C NMR spectrum of compound 40 (500 MHz, DMSO-d6) 
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Figure 7-45: The 1H NMR spectrum of compound 41 (500 MHz, DMSO-d6) 
 
 
Figure 7-46: The 13C NMR spectrum of compound 41 (500 MHz, DMSO-d6) 
 
 154 
 
 
Figure 7-47: The 1H NMR spectrum of compound 36 (500 MHz, DMSO-d6) 
 
 
Figure 7-48: The 13C NMR spectrum of compound 36 (500 MHz, DMSO-d6) 
